```
=> fil reg
FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   21 MAY 2002  HIGHEST RN 420086-04-0
DICTIONARY FILE UPDATES:  21 MAY 2002  HIGHEST RN 420086-04-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l43

L43  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2002 ACS
RN   153034-77-6  REGISTRY
CN   9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-
     hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   3-[7-Carboxy-9-oxo-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-
     hydroxyphenoxy]propoxy]-9H-xanthen-4-yl]propanoic acid
CN   LY 292728
FS   3D CONCORD
DR   186912-80-1
MF   C34 H29 F O9
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, DRUGUPDATES, MEDLINE, TOXCENTER,
       USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             18 REFERENCES IN FILE CA (1967 TO DATE)
              1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             17 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  135:352783

REFERENCE   2:  134:366682

REFERENCE   3:  134:366681
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

REFERENCE 4: 134:366680

REFERENCE 5: 134:366679

REFERENCE 6: 132:246369

REFERENCE 7: 129:289931

REFERENCE 8: 129:286007

REFERENCE 9: 129:255009

REFERENCE 10: 129:254996

L43 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 153034-73-2 REGISTRY
CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-, disodium salt (9CI) (CA INDEX NAME)
MF C34 H29 F O9 . 2 Na
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER
CRN (153034-77-6)



●2 Na

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366682

REFERENCE 2: 134:366681

REFERENCE 3: 134:366680

REFERENCE 4: 134:366679

REFERENCE 5: 126:74591

REFERENCE 6: 120:134251

=> d ide can tot l44

L44 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **262429-95-8** REGISTRY
CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H17 F3 N4 O8 S2

SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **262429-94-7** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 O4
SR CA
LC STN Files: CA, CAPLUS

These are other cmpds from Claim 15 (#17 - could not find)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **262429-93-6** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **262429-92-5** REGISTRY
CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H6 Cl4 F3 N O8 S3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

L44 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 256421-39-3 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, diammonium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 H3 N
SR CA
LC STN Files: CA, CAPLUS
CRN (130-85-8)



●2 NH_3

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:127714

L44 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 235083-90-6 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, strontium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . x Sr
SR CAS Registry Services
LC STN Files: CHEMLIST
Other Sources: TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●x Sr

L44 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 235083-88-2 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, zinc salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . x Zn
SR CAS Registry Services
LC STN Files: CHEMLIST
Other Sources: TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (130-85-8)



●x Zn

L44 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 220201-66-1 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, aluminum salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . x Al
SR CAS Registry Services
CRN (130-85-8)



●x Al

L44 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 207605-38-7 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt, hydrate (9CI) (CA INDEX NAME)
MF C23 H16 O6 . x H2 O . 2 Na
SR CAS Registry Services
CRN (130-85-8)



●2 Na

●x H_2O

L44 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **156005-50-4** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H32 O7
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 123:188623

REFERENCE 3: 121:141719

REFERENCE 4: 121:57380

L44 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **156005-27-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD

MF C27 H32 N2 O6
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 121:57380

L44 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **152608-30-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
MF C30 H33 F O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)
11 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366684

REFERENCE 2: 134:366682

REFERENCE 3: 134:366681

REFERENCE 4: 134:366680

REFERENCE 5: 134:366679

REFERENCE 6: 132:246369

REFERENCE 7: 129:144547

REFERENCE 8: 126:74591

REFERENCE 9: 125:58323

REFERENCE 10: 124:55467

L44 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **147612-00-8** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN LY 282201
FS 3D CONCORD
MF C26 H34 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:371777

REFERENCE 2: 134:371774

REFERENCE 3: 134:357589

REFERENCE 4: 132:246369

REFERENCE 5: 123:188623

REFERENCE 6: 120:322935

REFERENCE 7: 118:233824

L44 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **120072-59-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CGS 24115
CN SC 41390
CN SC 41930
FS 3D CONCORD
DR 157062-25-4
MF C28 H36 O7
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

55 REFERENCES IN FILE CA (1967 TO DATE)
54 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:161356

REFERENCE 2: 134:371777

REFERENCE 3: 134:371774

REFERENCE 4: 134:366684

REFERENCE 5: 134:357589

REFERENCE 6: 132:246369

REFERENCE 7: 132:203175

REFERENCE 8: 130:217617

REFERENCE 9: 127:239120

REFERENCE 10: 126:166481

L44 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 108652-29-5 REGISTRY
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, antimonate(III), hexasodium salt (7CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 Na . 2/3 Sb
SR CAOLD
LC STN Files: CAOLD
CRN (130-85-8)



●2 Na

2/3 Sb(III)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L44 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **97582-55-3** REGISTRY
CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H26 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 103:141966

L44 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 71607-30-2 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt, monohydrate (9CI) (CA INDEX NAME)
MF C23 H16 O6 . H2 O . 2 Na
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)
CRN (130-85-8)



●2 Na

● H_2O

L44 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 68226-95-9 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dipotassium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Dipotassium pamoate
MF C23 H16 O6 . 2 K
LC STN Files: CA, CAPLUS, CHEMLIST
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●2 K

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 107:39830

L44 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 68226-94-8 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dirubidium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 Rb
LC STN Files: CHEMLIST
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●2 Rb

L44 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 68226-93-7 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dicesium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 Cs
LC STN Files: CHEMLIST
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●2 Cs

L44 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 59413-58-0 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dilithium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 2 Li

CI COM
LC STN Files: CHEMLIST
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●2 Li

L44 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 53624-36-5 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, aluminum salt (3:1) (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 1/3 Al
CI COM
CRN (130-85-8)



●1/3 Al

L44 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 50857-37-9 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, didehydro deriv. (9CI) (CA INDEX NAME)
MF C23 H14 O6
CI IDS, COM

CM 1

CRN 130-85-8
CMF C23 H16 O6



L44 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 49609-89-4 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, tetrapotassium salt (9CI) (CA INDEX NAME)
MF C23 H16 O6 . 4 K
LC STN Files: CA, CAPLUS
CRN (130-85-8)



●4 K

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 79:115360

L44 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 15537-67-4 REGISTRY
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, monosodium salt (8CI) (CA INDEX NAME)
MF C23 H16 O6 . Na
CI COM
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)
CRN (130-85-8)



● Na

L44 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 7681-47-2 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, sodium salt (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, sodium salt (8CI)
OTHER NAMES:
CN Embonic acid sodium salt
CN Pamoic acid sodium salt
CN Sodium embonate
MF C23 H16 O6 . x Na
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



x Na

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:249165

REFERENCE 2: 76:140335

L44 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 7558-68-1 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, monopotassium salt (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, monopotassium salt (8CI)
OTHER NAMES:
CN Monopotassium pamoate
MF C23 H16 O6 . K
LC STN Files: BIOSIS, CHEMCATS, TOXCENTER
CRN (130-85-8)



● K

L44 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN 6640-22-8 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt (6CI, 7CI, 8CI)
OTHER NAMES:
CN Disodium 1,1'-methylenebis(2-hydroxy-3-naphthoate)
CN Disodium pamoate
CN Pamoic acid disodium salt
CN Sodium pamoate
MF C23 H16 O6 . 2 Na
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (130-85-8)



●2 Na

20 REFERENCES IN FILE CA (1967 TO DATE)
20 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:70079

REFERENCE 2: 132:339389

REFERENCE 3: 129:166217

REFERENCE 4: 120:30562

REFERENCE 5: 115:231824

REFERENCE 6: 107:39830

REFERENCE 7: 103:92844

REFERENCE 8: 103:42642

REFERENCE 9: 101:45858

REFERENCE 10: 100:159366

L44 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **145-63-1** REGISTRY
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di- (8CI)
OTHER NAMES:
CN 8,8'-[Ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-1,3,5-naphthalenetrisulfonic acid
CN Farma
CN Farma 939
CN Fourneau
CN Naganol
CN Naphuride
CN Suramin
CN Suramine
MF C51 H40 N6 O23 S6
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,

BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMLIST, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1119 REFERENCES IN FILE CA (1967 TO DATE)
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1122 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:322273

REFERENCE 2: 136:321001

REFERENCE 3: 136:319353

REFERENCE 4: 136:307351

REFERENCE 5: 136:304045

REFERENCE 6: 136:304044

REFERENCE 7: 136:257216

REFERENCE 8: 136:244034

REFERENCE 9: 136:243487

REFERENCE 10: 136:241690

L44 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **130-85-8** REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,2'-Dihydroxy-1,1'-dinaphthylmethane-3,3'-dicarboxylic acid
CN 4,4'-Methylenebis[3-hydroxy-2-naphthoic acid]
CN Bis(2-hydroxy-3-carboxy-1-naphthyl)methane
CN Embonic acid
CN Pamoic acid
FS 3D CONCORD
DR 122541-93-9, 67232-45-5, 50857-36-8, 108626-78-4, 47620-91-7
MF C23 H16 O6
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

105 REFERENCES IN FILE CA (1967 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
106 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:309958

REFERENCE 2: 136:273213

REFERENCE 3: 136:249165

REFERENCE 4: 136:189380

REFERENCE 5: 136:70079

REFERENCE 6: 135:226993

REFERENCE 7: 134:295673

REFERENCE 8: 134:18761

REFERENCE 9: 133:177242

REFERENCE 10: 133:785

=> d ide can

L78 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN **9004-10-8** REGISTRY
CN Insulin (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Actrapid
CN Actrapid HM
CN Actrapid MC
CN Decurvon
CN Endopancrine
CN Iletin
CN Insular
CN Insulin Injection
CN Insulyl
CN Iszilin
DR 8049-67-0, 8049-95-4, 9004-12-0, 9045-63-0, 9045-65-2, 9045-66-3, 9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8, 37243-75-7, 37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
72042 REFERENCES IN FILE CA (1967 TO DATE)
1454 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
72136 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:330564

REFERENCE 2: 136:330558

REFERENCE 3: 136:330513

REFERENCE 4: 136:330415

REFERENCE 5: 136:330319

REFERENCE 6: 136:325420

REFERENCE 7: 136:325415

REFERENCE 8: 136:325232

REFERENCE 9: 136:324791

REFERENCE 10: 136:324767

=>
=> d sta que l36
L32 STR



VAR G1=N-PR/I-PR
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 3
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L34 39 SEA FILE=REGISTRY SSS FUL L32
L35 15 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND 3/NR
L36 8 SEA FILE=REGISTRY ABB=ON PLU=ON L35 NOT N/ELS

=> d scan l36

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (2R)- (9CI)
MF C28 H36 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (+)- (9CI)
MF C28 H36 O7

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[[5-(4-acetyl-3-methoxy-2-propylphenoxy)pentyl]oxy]-3,4-dihydro-8-propyl- (9CI)
MF C30 H40 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(2-ethyl-5-hydroxy-4-methoxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI)
MF C25 H32 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI)
MF C28 H36 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[4-acetyl-3-methoxy-2-(2-propenyl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI)
MF C28 H34 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-, (-)- (9CI)
MF C28 H36 O7

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 8 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-[3-[3-methoxy-4-(2-methyl-1-oxopropyl)-2-propylphenoxy]propoxy]-8-propyl- (9CI)
MF C30 H40 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002
E HELMERHORST E/AU
L1 17 S E3,E4,E5
E PLEWRIGHT B/AU
L2 1 S E4
L3 17 S L1,L2
E CURTIN/PA,CS
L4 3783 S E3-E49
L5 5 S L3 AND L4
L6 13 S L3 AND ?INSULIN?
L7 1 S L6 AND (NONPEPTID? OR NON PEPTID?)
L8 1 S L7 AND L5,L6
SEL RN

FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002
L9 14 S E1-E14
L10 13 S L9 NOT INSULIN
L11 4 S L9 AND F/ELS
L12 1 S L11 AND 5/NR
L13 12 S L10 NOT L12
L14 8 S L13 AND OC5-C6/ES
L15 6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
L16 6 S L13 NOT L15
L17 12 S L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002
L18 16 S L3 NOT L8
SEL RN

FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002

```
L19          13 S E15-E27
L20          12 S L19 NOT L9
L21       55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
L22         807 S L21 AND 26/C
L23         131 S L22 AND 5/O
L24          59 S L23 AND METHOXY
L25          46 S L24 NOT N/ELS
L26           4 S L22 AND C26H34O5
L27             STR
L28           0 S L27 CSS
L29           0 S L27 SAM
L30         437 S C26H34O5/MF
L31           6 S L30 AND 46.150.18/RID AND OC5-C6/ES
L32             STR L27
L33           1 S L32
L34          39 S L32 FUL
                SAV L34 HOPE400/A
L35          15 S L34 AND 3/NR
L36           8 S L35 NOT N/ELS
                SEL RN L20
                SEL RN L17
L37         763 S E40-E51/CRN
L38          63 S L37 NOT (COMPD OR MXS/CI)
L39          51 S L38 NOT WITH
L40          19 S L39 AND 4/NR
L41          18 S L40 NOT UNSPECIFIED
                SEL RN L12
L42           1 S E52/CRN
L43           2 S L12,L42
L44          30 S L17,L41

     FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

     FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002
L45           0 S L43

     FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002
L46          21 S L43
L47      140567 S INSULIN
L48      334734 S GLUCOSE
                S INSULIN/CN OR GLUCOSE/CN

     FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002
L49           2 S GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002
L50      121055 S L49

     FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002
L51           1 S INSULIN/CN

     FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002
L52       71961 S L51
L53      172109 S L52 OR L50
L54          21 S L46 OR LY292728 OR LY()(292728 OR 292 728)
L55          16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)
L56           1 S L54 AND L3,L4
L57           1 S L54 AND L47,L48,L53
L58           1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L59           0 S L54 AND (?OBESIT? OR ?OBESE?)
L60           1 S L56-L58
                E INSULIN/CT
                E E24+ALL
```

```
L61         9442 S E11,E10
L62            1 S L54 AND L61
L63            1 S L60,L62
L64         1314 S L44
L65           61 S L64 AND L47,L48,L53,L61
L66         9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L67          458 S L61 AND (?OBESIT? OR ?OBESE?)
L68            8 S L65 AND L66,L67
L69         6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR
L70           34 S L69 AND L65
L71           33 S L70 NOT L68
L72            1 S L71 AND ?DIABET?
L73            2 S L63,L72
L74            9 S L51 AND L64
L75            8 S L74 NOT APOPTOSIS/TI
L76            9 S L73,L75
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002
L77           14 S E1-E14
L78            1 S L77 NOT L43,L44

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 May 2002  VOL 136 ISS 21
FILE LAST UPDATED: 22 May 2002  (20020522/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> d l76 all hitstr tot

L76  ANSWER 1 OF 9  HCAPLUS  COPYRIGHT 2002 ACS
AN   2000:209933  HCAPLUS
DN   132:246369
TI   Use of non-peptidyl compounds for the treatment of insulin
     -related ailments
IN   Helmerhorst, Erik; Plewright, Brian Scott
PA   Curtin University of Technology, Australia
SO   PCT Int. Appl., 129 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
```

App'l.

IC ICM A61K038-28
ICS A61K031-19; A61K031-35
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000016798	A1	20000330	WO 1999-AU786	19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9960707	A1	20000410	AU 1999-60707	19990917
EP 1115422	A1	20010718	EP 1999-947113	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI AU 1998-6091 A 19980922
WO 1999-AU786 W 19990917
OS MARPAT 132:246369
AB The present invention relates to the use of at least a non-peptidyl compd. as a biol. modulator of **insulin** activity or **insulin** -related activity for the treatment of **insulin**-related diseases. Non-peptidyl compds. of the present invention exert their effects by mimicking amino acids spatially located on **insulin**, enabling those compds. to bind to the **insulin** receptor or **insulin** -like receptor causing biol. modulation of the activity of the receptor. A method for identifying a non-peptidyl compd. comprises the steps of: (1) comparing the 3D structure of the non-peptidyl compd. with a 3D pharmacophore of an active site of **insulin**, and (2) selecting a non-peptidyl compd. The compds. may act either as agonists or antagonists of **insulin** or **insulin**-like activity. Pharmaceutical compns. contg. chem. compds. capable of modulating the biol. activity of **insulin** are also claimed. For example, 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylic acid] (IM 025) was an antagonist of **insulin** action. IM 025 caused a dose-dependent decrease in the incorporation of 32P into FYF peptide in **insulin**-stimulated tubes and inhibited **glucose** transport in 3T3L1 cells, with IC50 of 150 and 170 .mu.M, resp. 2,4-Dichloro-6-[N-(trifluoromethanesulfonyl)sulfamoylphenyl-3,5-dichloro-2-hydroxybenzene] sulfonate (IM 103) was an agonist of **insulin** action displaying a biphasic biol. dose response curve with an apex at concn. of 110 .mu.M and an apparent EC50 of 45 .+-. 7 .mu.M.
ST nonpeptidyl **insulin** receptor agonist antagonist **antidiabetic**
IT **Antidiabetic** agents
Pharmacophores
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)
IT **Insulin receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)
IT **130-85-8 145-63-1 97582-55-3 120072-59-5 147612-00-8 152608-30-5 153034-77-6 156005-27-5 156005-50-4**

262429-92-5 262429-93-6 262429-94-7
262429-95-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

IT **9004-10-8, Insulin,** biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Aguilar-Bryan, L; J Biol Chem 1990, P8218 HCAPLUS
(2) Bahn, H; 1978, P5
(3) Djuric, S; J Med Chem 1989, V32(6), P1145 HCAPLUS
(4) Eli Lilley And Company; EP 132366 1985 HCAPLUS
(5) Eli Lilley And Company; WO 9517183 1995 HCAPLUS
(6) Harper, R; J Med Chem 1994, V37, P2411 HCAPLUS
(7) Mount Sinai School Of Medicine; AU 9055415 1990 HCAPLUS
(8) Novo Nordisk AS; AU 8654495 1986 HCAPLUS
(9) Novo Nordisk AS; AU 8662066 1987 HCAPLUS
(10) Novo Nordisk AS; AU 8813976 1988 HCAPLUS
(11) Novo Nordisk AS; AU 8822636 1990 HCAPLUS
(12) Novo Nordisk AS; AU 9048344 1990 HCAPLUS
(13) Sawyer, J; J Med Chem 1993, V36, P3982 HCAPLUS

IT **130-85-8 145-63-1 97582-55-3**
120072-59-5 147612-00-8 152608-30-5
153034-77-6 156005-27-5 156005-50-4
262429-92-5 262429-93-6 262429-94-7
262429-95-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)

RN 130-85-8 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)



RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 97582-55-3 HCAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)



RN 120072-59-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 147612-00-8 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 152608-30-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 153034-77-6 HCAPLUS
CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)



RN 156005-27-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 156005-50-4 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 262429-92-5 HCAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 262429-93-6 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)



RN 262429-94-7 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)



RN 262429-95-8 HCAPLUS
CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)



IT **9004-10-8**, **Insulin**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-peptidyl compds. modulating **insulin** activity by mimicking amino acid residues spatially located on **insulin** and binding to **insulin** receptors)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:208513 HCAPLUS
DN 131:53970
TI Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose
AU Yasunari, Kenichi; Kohno, Masakazu; Kano, Hiroaki; Yokokawa, Koji; Minami, Mieko; Yoshikawa, Junichi
CS First Department of Internal Medicine, Osaka City University Medical School, Osaka, 545-8586, Japan
SO Circulation (1999), 99(10), 1370-1378
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
CC 1-12 (Pharmacology)
Section cross-reference(s): 14
AB To explore the role of intracellular oxidative stress in high glucose-induced atherogenesis, we examd. the effect of probucol and/or .alpha.-tocopherol on the migration and growth characteristics of cultured rabbit coronary vascular smooth muscle cells (VSMCs). Chronic high-glucose-medium (22.2 mmol/L) treatment increased platelet-derived growth factor (PDGF)-BB-mediated VSMC migration, [3H]thymidine incorporation, and cell no. compared with VSMCs treated with normal-glucose medium (5.6 mmol/L+16.6 mmol/L mannose). Probucol and .alpha.-tocopherol significantly suppressed high glucose-induced increase in VSMC migration, cell no., and [3H]thymidine incorporation. Probucol and .alpha.-tocopherol suppressed high glucose-induced elevation of the

cytosolic ratio of NADH/NAD+, phospholipase D, and membrane-bound protein kinase C activation. Probucol, .alpha.-tocopherol, and calphostin C improved the high glucose-induced suppression of insulin-mediated [3H]deoxyglucose uptake. Chronic high-glucose treatment increased the oxidative stress, which was significantly suppressed by probucol, .alpha.-tocopherol, suramin, and calphostin C. These findings suggest that probucol and .alpha.-tocopherol may suppress high glucose-induced VSMC migration and proliferation via suppression of increases in the cytosolic ratio of free NADH/NAD+, phospholipase D, and protein kinase C activation induced by high glucose, which result in redn. in intracellular oxidative stress.

ST glucose coronary atherogenesis antioxidant probucol tocopherol

IT Platelet-derived growth factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(BB; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT Atherosclerosis
Oxidative stress, biological
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT Artery
(coronary; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT Antioxidants
(pharmaceutical; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT Blood vessel
(smooth muscle; antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT 50-99-7, D-Glucose, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT **145-63-1**, Suramin **9004-10-8**, Insulin, biological studies
121263-19-2, Calphostin C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT 59-02-9, .alpha.-Tocopherol 23288-49-5, Probucol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

IT 9001-87-0, Phospholipase D 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bass, D; J Immunol 1983, V130, P1910 HCAPLUS
(2) Baynes, J; Diabetes 1991, V40, P405 HCAPLUS

(3) Bornfeldt, K; J Clin Invest 1994, V93, P1266 HCAPLUS
(4) Despres, J; N Engl J Med 1996, V334, P952 HCAPLUS
(5) Farese, R; J Biol Chem 1993, V268, P19949 HCAPLUS
(6) Hansen, P; Am J Physiol 1997, V273, PE28 HCAPLUS
(7) Hansen, P; Endocrinol Metab V36
(8) Kellerer, M; Diabetes 1994, V43, P447 HCAPLUS
(9) King, G; J Clin Invest 1983, V71, P974 HCAPLUS
(10) Kunisaki, M; Diabetes 1994, V43, P1372 HCAPLUS
(11) Lassegue, B; Biochem J 1993, V292, P509 HCAPLUS
(12) Machlin, L; FASEB J 1987, V1, P441 HCAPLUS
(13) Ohara, Y; Arterioscler Thromb Vasc Biol 1994, V14, P1007 HCAPLUS
(14) Parthasarathy, S; J Clin Invest 1986, V77, P641 HCAPLUS
(15) Parthasarathy, S; J Clin Invest 1992, V89, P1618 HCAPLUS
(16) Rao, G; Circ Res 1992, V70, P593 HCAPLUS
(17) Ross, R; N Engl J Med 1986, V314, P488 MEDLINE
(18) Saltiel, A; Diabetes 1996, V45, P1661 HCAPLUS
(19) Stein, B; Circulation 1995, V91, P979 MEDLINE
(20) Suudaresan, M; Science 1995, V270, P296
(21) Vinson, J; Diabetes 1989, V38, P1036 HCAPLUS
(22) Wallenstein, S; Circ Res 1980, V47, P1 MEDLINE
(23) Williams, B; Diabetes 1992, V41, P1464 HCAPLUS
(24) Williamson, J; Diabetes 1993, V42, P801 HCAPLUS
(25) Yasunari, K; Arterioscler Thromb Vasc Biol 1995, V15, P2207 HCAPLUS
(26) Yasunari, K; Circ Res 1997, V81, P953 HCAPLUS
(27) Yasunari, K; Hypertension 1996, V28, P159 HCAPLUS

IT **145-63-1**, Suramin **9004-10-8**, Insulin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose)

RN 145-63-1 HCAPLUS

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:546945 HCAPLUS
DN 122:282211
TI Method of detecting cytopenia that is mediated by drug-dependent antibody binding to blood cells
IN Aster, Richard H.; Curtis, Brian R.
PA Blood Center of Southeastern Wisconsin, Inc., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-53
ICS G01N033-554; G01N033-555
CC 1-1 (Pharmacology)
Section cross-reference(s): 9, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9508116	A1	19950323	WO 1994-US10333	19940915
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5585243	A	19961217	US 1993-120837	19930915
	AU 9476208	A1	19950403	AU 1994-76208	19940915
PRAI	US 1993-120837		19930915		
	WO 1994-US10333		19940915		

AB Drug-dependent antibodies that bind to granulocytes, erythrocytes, platelets or membrane proteins derived from these cells, in the presence of a drug, but not in its absence, can be detected using a sensitive assay. Detection of the drug-dependent antibodies permits diagnosis of cytopenia mediated by the drug. The method is applicable to a wide variety of drugs. Flow cytom. histograms for e.g. detection of probenecid-dependent antibodies that bind red blood cells are included, and mean 142platelet immunofluorescence values obtained in studies with drug-induced antibodies are tabulated.
ST drug cytopenia diagnosis antibody blood cell; immunoassay drug mediated cytopenia diagnosis; antibody drug dependent cytopenia diagnosis
IT Agranulocytosis
Blood analysis
Blood platelet
Erythrocyte

Pharmaceuticals
Urine analysis
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Interferons
Sulfonamides
Urethane polymers, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Complement
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Albumins, analysis
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Antibodies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Pharmaceutical natural products
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
(digitalis, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Blood corpuscle
(disease, cytopenia, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Blood platelet
(disease, thrombocytopenia, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Cytometry
(flow, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Leukocyte
(granulocyte, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Anemia (disease)
(hemolytic, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(membrane-assocd., detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT Sulfonamides
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
(sulfonylureas, detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT 50-12-4, Mesantoin 50-18-0, Cyclophosphamide 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 51-06-9, Procainamide 51-21-8, 5-Fluorouracil 51-52-5, Propylthiouracil 52-01-7, Spironolactone 52-67-5, Penicillamine 52-86-8, Haloperidol 53-86-1, Indomethacin 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-85-3, Isoniazid 55-63-0, Nitroglycerin 56-53-1, Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-53-4, Meprobamate 57-66-9, Probenecid 57-67-0, Sulfaguanidine 57-92-1, Streptomycin, biological studies 58-14-0, Pyrimethamine 58-15-1, Aminopyrine 58-25-3,

Chlordiazepoxide 58-38-8, Prochlorperazine 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 58-94-6D, Thiazide, derivs. 59-66-5, Acetazolamide 59-92-7, L-Dopa, biological studies 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-32-5, Methicillin 61-72-3, Cloxacillin 62-44-2, Phenacetin 63-74-1, Sulfanilamide 64-77-7, Tolbutamide 65-49-6, p-Aminosalicylic acid 67-20-9, Nitrofurantoin 68-89-3, Metamizole 69-23-8, Fluphenazine 69-53-4, Ampicillin 70-51-9, Desferrioxamine 71-63-6, Digitoxin 72-14-0, Sulfathiazole 74-55-5, Ethambutol 76-75-5, Thiopental 77-02-1 77-36-1, Chlorthalidone 77-65-6, Carbromal 79-57-2, Oxytetracycline 80-08-0 80-35-3, Sulfamethoxypyridazine 81-81-2, Warfarin 85-73-4, Phthalylsulfathiazole 86-54-4, Hydralazine 91-75-8, Antazoline 92-84-2D, Phenothiazine, derivs. 94-20-2, Chlorpropamide 96-83-3, Iopanoic acid 97-77-8, Disulfiram 99-66-1, Valproic acid 100-33-4, Pentamidine 103-90-2, Acetaminophen 110-85-0, Piperazine, biological studies 113-45-1, Methylphenidate 113-92-8 114-07-8, Erythromycin 115-67-3, Paramethadione 116-43-8 117-96-4, Diatrizoate 118-42-3, Hydroxychloroquine 122-11-2, Sulfadimethoxine 125-33-7, Primidone 125-40-6, Butabarbitone 125-84-8, Aminoglutethimide 127-56-0 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 129-20-4, Oxyphenbutazone 130-95-0, Quinine 135-07-9 137-58-6, Lidocaine 141-90-2, Thiouracil 144-82-1, Sulfamethizole **145-63-1**, Suramin 148-24-3, 8-Quinolinol, biological studies 148-82-3, Melphalan 153-61-7, Cephalothin 154-21-2, Lincomycin 154-42-7, Thioguanine 298-46-4, Carbamazepine 303-81-1, Novobiocin 315-30-0, Allopurinol 339-44-6, Glymidine 359-83-1, Pentazocine 364-98-7, Diazoxide 389-08-2, Nalidixic acid 396-01-0, Triamterene 439-14-5 474-25-9, Chenodeoxycholic acid 519-98-2, Noraminopyrine 525-66-6, Propranolol 528-92-7, Allylisopropylacetylurea 554-57-4, Methazolamide 555-30-6, .alpha.-Methyldopa 561-27-3, Heroin 599-79-1, Sulfasalazine 636-54-4, Clopamide 644-62-2 709-98-8, Propanil 723-46-6 738-70-5, Trimethoprim 1397-89-3, Amphotericin B 1402-38-6, Actinomycin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5, Doxepin 1951-25-3, Amiodarone 2033-94-5, Centalun 3737-09-5, Disopyramide 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5534-95-2, Pentagastrin 5786-21-0, Clozapine 6452-71-7, Oxprenolol 6990-06-3, Fusidic acid 7439-93-2D, Lithium, salts 8025-81-8, Spiramycin 8064-90-2 **9004-10-8**, Insulin, biological studies 10238-21-8, Glibenclamide 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 13292-46-1, Rifampicin 14028-44-5, Amoxapine 14769-73-4, Levamisole 15307-86-5, Diclofenac 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 16034-77-8, Iocetamic acid 17230-88-5, Danazol 18323-44-9, Clindamycin 18378-89-7, Plicamycin 20830-75-5, Digoxin 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-54-8, Carbimazole 24219-97-4, Mianserin 24526-64-5, Nomifensine 25803-14-9, Clometacine 26171-23-3, Tolmetin 31828-71-4, Mexiletine 31879-05-7, Fenoprofen 32986-56-4, Tobramycin 34444-01-4, Cephamandole 36322-90-4, Piroxicam 37300-21-3 38194-50-2, Sulindac 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 41708-72-9, Tocainide 42399-41-7, Diltiazem 51234-28-7, Benoxaprofen 51481-61-9, Cimetidine 51481-65-3, Mezlocillin 51803-78-2, Nimesulide 54350-48-0, Etretinate 55142-85-3, Ticlopidine 59865-13-3, Cyclosporine A 60719-84-8, Amrinone 61477-96-1, Piperacillin 62054-23-3, Phthalazinol 62571-86-2, Captopril 63469-19-2, Apalcillin 64872-76-0, Butoconazole 64952-97-2, Moxalactam 66357-35-5, Ranitidine 69655-05-6, Didanosine 69712-56-7, Cefotetan 70052-12-9 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73384-59-5 76824-35-6, Famotidine 79517-01-4, Octreotide acetate 79902-63-9, Simvastatin 81103-11-9, Clarithromycin 86386-73-4, Fluconazole 87626-55-9, Flavone-8-acetic acid 99614-02-5, Ondansetron 100817-46-7, Stibogluconic acid
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)

(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT 67-68-5, analysis
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

IT **145-63-1**, Suramin **9004-10-8**, Insulin, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BIOL (Biological study); PROC (Process)
(detection of cytopenia mediated by drug-dependent antibody binding to blood cells)

RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1994:430214 HCAPLUS

DN 121:30214
TI Mass spectrometric molecular-weight determination of highly acidic compounds of biological significance via their complexes with basic polypeptides
AU Juhasz, Peter; Biemann, Klaus
CS Dep. Chem., Massachusetts Institute of Technol., Cambridge, MA, 02139-4307, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(10), 4333-7
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English
CC 9-5 (Biochemical Methods)
Section cross-reference(s): 73
AB Highly acidic compds. that are difficult to ionize by matrix-assisted laser desorption ionization give excellent spectra when mixed with a basic peptide or protein to form a noncovalent complex. This phenomenon makes it possible to det. the mol. wts. of polysulfated, polysulfonated, and polyphosphorylated biomols. such as cysteic acid-contg. peptides, oligonucleotides, heparin-derived oligosaccharides, and suramin (a drug contg. 2 trisulfonated naphthalene moieties). Peptides and small proteins rich in arginine were used as the basic components. The extent of complex formation correlates with the no. of phosphate and sulfate groups in the acidic component and with the no. of arginines in the basic component. Neither the acidic amino acid residue aspartic and glutamic acid nor the basic lysine and histidine contribute to complex formation. For oligonucleotides, histone H4 was found to be the best complexing agent investigated. The anal. utility of the complex formation is demonstrated by the mol.-mass detn. of acidic compds. from 500 to 6000 Da at the picomole or sub-picomole level with an accuracy of .+-.0.1% or better and by the absence of alkali cation adducts.
ST acidic biochem mol wt detn; mass spectrometry acidic compd mol wt; basic polypeptide complex acidic compd mass
IT Mass spectrometry
(MALDI (matrix-assisted laser desorption ionization), mol. wt. of highly acidic biol. compds. detn. with basic polypeptides for complex formation and)
IT Molecular weight
(detn. of, of highly acidic biol. compds., with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Oligosaccharides
RL: ANST (Analytical study)
(heparin-derived, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Histones
RL: ANST (Analytical study)
(H4, calf thymus, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
IT Peptides, uses
Proteins, specific or class
RL: USES (Uses)
(arginine-contg., mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)
IT Molecules
(biochem., highly acidic, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)
IT Nucleotides, properties
RL: PRP (Properties)
(oligo-, mol. wt. of, detn. of, with basic polypeptides for complex

formation and matrix-assisted laser desorption ionization mass spectrometry)

IT Nucleotides, properties
RL: PRP (Properties)
(oligo-, deoxyribo-, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)

IT 54-20-6, 5-(Trifluoromethyl)uracil 110-15-6, Butanedioic acid, uses 118-92-3, Anthranilic acid 331-39-5, Caffeic acid 530-59-6, Sinapinic acid 28166-41-8, .alpha.-Cyano-4-hydroxycinnamic acid
RL: ANST (Analytical study)
(as matrix in MALDI mass spectrometric mol. wt. detn. of highly acidic biol. compds. via their complexes with basic polypeptides)

IT 60267-61-0, Ubiquitin
RL: ANST (Analytical study)
(bovine, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)

IT 9007-43-6, Cytochrome c, uses
RL: USES (Uses)
(horse, mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)

IT 20449-79-0P, Melittin 60482-95-3P, Neurotensin(8-13) 61214-51-5P 77259-54-2P, Dynorphin(1-9) 81493-98-3P 88894-91-1P 123251-89-8P 155964-83-3P 155964-84-4P 155964-85-5P
RL: PREP (Preparation)
(mol. wt. detn. of highly acidic biol. compds. by formation of complex with, matrix-assisted laser desorption ionization mass spectrometry in)

IT **145-63-1**, Suramin 110577-00-9
RL: PRP (Properties)
(mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)

IT 55508-38-8
RL: PRP (Properties)
(mol. wt. of, detn. of, with calf thymus histone H4 for complex formation and matrix-assisted laser desorption ionization mass spectrometry)

IT 9005-49-6, Heparin, biological studies
RL: BIOL (Biological study)
(oligosaccharides derived from, mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)

IT **9004-10-8**, Insulin, analysis
RL: ANST (Analytical study)
(oxidized A chain of bovine, MALDI mass spectra of mixt. of bovine ubiquitin and)

IT **145-63-1**, Suramin
RL: PRP (Properties)
(mol. wt. of, detn. of, with basic polypeptides for complex formation and matrix-assisted laser desorption ionization mass spectrometry)

RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **9004-10-8**, Insulin, analysis
RL: ANST (Analytical study)
(oxidized A chain of bovine, MALDI mass spectra of mixt. of bovine ubiquitin and)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:6982 HCAPLUS
DN 118:6982
TI Preparation of [(heterocyclyl)(alkyl)]phenyl amidines and guanidines as hypoglycemics.
IN Gopalan, Balasubramanian
PA Boots Co., PLC, UK
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 123 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
IC ICM C07D211-56
ICS C07D207-14; C07D233-02; C07D239-04; C07D265-30; C07D223-12
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1057648	A	19920108	CN 1990-103295	19900629
	CN 1037346	B	19980211		

OS CASREACT 118:6982; MARPAT 118:6982

GI



I

AB The title compds. [I; R1, R2 = (methoxy) aliph. hydrocarbyl, cycloalkyl; or NR1R2 = N-contg. heterocyclyl; R3 = alkyl, cycloalkyl, (substituted) amino; R5 = (methoxy) aliph. hydrocarbyl; R6 = H, (substituted) alkyl, cycloalkyl; R7 = H,alkyl, halo, methoxy, CO2Me, SO2Me; R3R5 may form part of a ring; with provisos] are prepd. E.g., 1-benzyl-3-methyl-2-pyrrolidinone in benzene contg. POCl3 was heated with 4-(2-aminophenyl)morpholine at 70.degree. for 24 h to give 4-[2-(1-benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine. This decreased the blood sugar level by .gtoreq.25% in rats 2 or 4 h after they were injected s.c. with **glucose**. Pharmaceuticals contg. I were formulated.

ST amidine heterocyclylalkylphenyl prepn hypoglycemic; guanidine heterocyclylalkylphenyl prepn hypoglycemic; heterocyclylalkylphenyl amidine guanidine; hypoglycemic amidine guanidine

IT **Antidiabetics** and Hypoglycemics
([(heterocyclyl)(alkyl)]phenyl amidines and guanidines)

IT Amidines
RL: SPN (Synthetic preparation); PREP (Preparation)
(aryl, prepn. of, as hypoglycemics)

IT 131679-02-2, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine difumarate
RL: RCT (Reactant)
(234prepn. of, as hypoglycemic)

IT 131675-72-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine 131675-74-6P, 4-[2-(1-Methyl-2-piperidinylideneamino)phenyl]morpholine 131675-75-7P 131675-76-8P 131675-77-9P 131675-78-0P 131675-80-4P 131675-81-5P 131675-82-6P 131675-83-7P, 4-[2-(1,3,3-Trimethyl-2-pyrrolidinylideneamino)phenyl]morpholine 131675-84-8P 131675-86-0P 131675-87-1P 131675-88-2P 131675-90-6P 131675-91-7P 131675-93-9P 131675-94-0P 131675-95-1P 131675-96-2P 131675-97-3P 131675-98-4P 131675-99-5P 131676-01-2P 131676-02-3P, 4-[4-Chloro-2-(2-piperidinylideneamino)phenyl]morpholine 131676-03-4P 131676-04-5P 131676-05-6P 131676-06-7P 131676-07-8P 131676-08-9P 131676-09-0P 131676-10-3P 131676-13-6P 131676-14-7P, 4-[2-(3-Methyl-2-pyrrolidinylideneamino)phenyl]morpholine fumarate 131676-15-8P 131676-16-9P 131676-17-0P, 1-Butyl-2-(2-morpholinophenyl)-3-acetamidine 131676-19-2P 131676-21-6P 131676-23-8P 131676-25-0P 131676-26-1P 131676-27-2P 131676-28-3P 131676-29-4P 131676-30-7P 131676-31-8P 131676-32-9P 131676-33-0P 131676-34-1P 131676-35-2P 131676-36-3P 131676-37-4P 131676-38-5P 131676-39-6P 131676-40-9P 131676-41-0P 131676-42-1P 131676-43-2P 131676-44-3P 131676-45-4P 131676-46-5P 131676-47-6P 131676-48-7P 131676-49-8P 131676-50-1P 131676-51-2P 131676-52-3P 131676-53-4P 131676-54-5P 131676-55-6P 131676-56-7P

131676-57-8P 131676-59-0P 131676-60-3P 131676-62-5P 131676-63-6P
131676-64-7P 131676-65-8P 131676-66-9P 131676-67-0P 131676-69-2P
131676-70-5P 131676-71-6P 131676-72-7P 131676-73-8P 131676-74-9P
131676-75-0P 131676-77-2P 131676-78-3P, N-(2-
Morpholinophenyl)acetamidine 131676-79-4P, N-(5-Methyl-2-
morpholinophenyl)acetamidine 131676-80-7P, N-(2-
Morpholinophenyl)propionamidine 131676-81-8P, N-(2-
Morpholinophenyl)butyramidine 131676-83-0P, N-(2-
Morpholinophenyl)isobutyramidine 131676-85-2P, N-(5-Fluoro-2-
morpholinophenyl)isobutyramidine 131676-86-3P, N-(2-
Morpholinophenyl)pentanamidine 131676-87-4P, N-(2-
Morpholinophenyl)neopentanamidine 131676-88-5P 131676-89-6P
131676-90-9P 131676-91-0P 131676-94-3P 131676-97-6P 131676-98-7P
131676-99-8P 131677-00-4P 131677-01-5P, 4-(2-[1-(2-Cyanoethyl)-2-
piperidinylideneamino]phenyl)morpholine 131677-02-6P,
4-[2-(3-Morpholinylideneamino)phenyl]morpholine hydrochloride
131677-05-9P 131677-06-0P 131677-08-2P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-09-3P 131677-10-6P
131677-11-7P 131677-12-8P 131677-13-9P 131677-14-0P 131677-15-1P
131677-17-3P 131677-18-4P 131677-20-8P 131677-22-0P 131677-23-1P
131677-24-2P 131677-26-4P 131677-28-6P 131677-29-7P 131677-30-0P
131677-31-1P 131677-35-5P 131677-36-6P, 1-Ethyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-37-7P, 1-Allyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-38-8P, 1-Butyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-39-9P, 1-Pentyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-40-2P, 4-(2-[1-Methyl-3-(2-methoxyethyl)-
2-imidazolidinylideneamino]phenyl)morpholine 131677-41-3P,
4-(2-[1-Methyl-3-(2-methoxyethyl)-2-imidazolidinylideneamino]phenyl)morpho
line monofumarate 131677-42-4P, 4-(2-[1-Methyl-3-(2-hydroxyethyl)-2-
imidazolidinylideneamino]phenyl)morpholine 131677-43-5P,
N,N-Dimethyl-N'-(2-morpholinophenyl)morpholine-4-formamidine
131677-44-6P 131677-45-7P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]thiamorpholine 1-oxide 131677-46-8P,
4-[2-(2-Imidazolidenylideneamino)phenyl]morpholine 131677-47-9P,
4-[2-(1-Methyl-2-imidazolidinylideneamino)phenyl]morpholine 131677-48-0P
131677-49-1P 131677-50-4P 131677-51-5P 131677-52-6P 131677-53-7P
131677-54-8P 131677-55-9P 131677-56-0P 131677-58-2P 131677-59-3P
131677-60-6P 131677-61-7P 131677-62-8P 131677-63-9P 131677-64-0P
131677-65-1P 131677-66-2P 131677-67-3P 131677-68-4P 131677-69-5P
131677-70-8P 131677-71-9P 131677-72-0P 131677-73-1P 131677-74-2P
131677-75-3P 131677-76-4P 131677-77-5P 131677-78-6P 131677-79-7P
131677-80-0P 131677-81-1P, 4-[2-(4-Methyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-82-2P,
4-[2-(4,5-Dimethyl-2-imidazolidinylideneamino)phenyl]morpholine
131677-83-3P, 4-[2-(4,5-Dimethyl-1-(2-hydroxyethyl)-2-
imidazolidinylideneamino)phenyl]morpholine 131677-84-4P,
4-[2-(1-Methylperhydropyrimidin-2-ylideneamino)phenyl]morpholine
131677-85-5P, 2-(2-Morpholinophenylimino)-1,3-diazacycloheptane
131677-86-6P, 1,1-Dimethyl-2-(morpholinophenyl)guanidine 131677-87-7P,
1,3-Dimethyl-2-(morpholinophenyl)guanidine 131677-88-8P,
1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine 131677-89-9P,
1-Ethyl-2-(2-morpholinophenyl)-3-methylguanidine 131677-90-2P,
1,3-Diethyl-2-(2-morpholinophenyl)guanidine 131677-91-3P,
4-(2-[1-(2-Acetoxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine
131677-93-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine
131677-94-6P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine
131677-96-8P, 1-(2-Methylthioethyl)-2-(2-morpholinophenyl)guanidine
131677-97-9P 131677-98-0P, 1-Propyl-2-morpholinophenyl-3-methylguanidine
monofumarate 131677-99-1P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-
methoxyethyl)guanidine 131678-01-8P, 1-Cyclopentyl-2-(2-
morpholinophenyl)-3-methylguanidine 131678-02-9P, 1-Cyclopenyl-2-(2-
morpholinophenyl)-3-methylguanidine monofumarate 131678-03-0P,
N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine 131678-08-5P,

1,3-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine fumarate
131678-09-6P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-
methylphenyl)morpholine 131678-12-1P, 1-Butyl-2-(5-methyl-2-
morpholinophenyl)-3-methylguanidine 131678-13-2P 131678-14-3P
131678-15-4P 131678-16-5P 131678-17-6P 131678-18-7P 131678-19-8P,
1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine 131678-20-1P,
1,3-Dipropyl-2-(2-morpholinophenyl)guanidine 131678-21-2P,
1,3-Dipropyl-2-(2-morpholinophenyl)guanidine hemifumarate 131678-22-3P
131678-23-4P 131678-24-5P 131678-25-6P 131678-26-7P 131678-27-8P
131678-28-9P 131678-29-0P 131678-30-3P 131678-31-4P 131678-32-5P
131678-33-6P 131678-35-8P 131678-36-9P 131678-38-1P 131678-39-2P
131678-40-5P 131678-41-6P 131678-43-8P 131678-44-9P 131678-45-0P
131678-46-1P, 1,1-Dimethyl-2-(5-methoxycarbonyl-2-
morpholinophenyl)guanidine 131678-47-2P 131678-48-3P 131678-49-4P
131678-50-7P 131678-51-8P 131678-52-9P 131678-53-0P 131678-54-1P
131678-55-2P 131678-56-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypoglycemic)

IT 131678-57-4P 131678-58-5P 131678-59-6P, 1,1-Dimethyl-2-(5-chloro-2-
morpholinophenyl)guanidine 131678-60-9P, 1,1-Dimethyl-2-(5-fluoro-2-
morpholinophenyl)guanidine 131678-61-0P, 1,1-Dimethyl-2-(3-methyl-2-
morpholinophenyl)guanidine 131678-62-1P, 1,1-Dimethyl-2-(5-isobutyl-2-
morpholinophenyl)guanidine 131678-63-2P, 1,1-Dimethyl-2-(5-
methylsulfinyl-2-morpholinophenyl)guanidine 131678-64-3P 131678-65-4P
131678-66-5P 131678-67-6P 131678-70-1P 131678-71-2P 131678-72-3P,
4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine
monotartrate 131678-74-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine
monotartrate 131678-75-6P, 1,1-Dimethyl-2-(5-methyl-2-
morpholinophenyl)guanidine monohydrochloride 131678-76-7P,
1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monohydrochloride
131678-78-9P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzy
l]morpholine 131678-79-0P, 4-[4-Chloro-2-(1,3-dimethyl-2-
imidazolidinylideneamino)benzyl]morpholine monofumarate 131678-80-3P,
N-(2-Morpholinomethylphenyl)morpholine-4-formamidine 131678-81-4P,
N-(2-Morpholinophenyl)neopentanamidine monofumarate 131678-84-7P,
N-Methyl-N'-(2-morpholinomethylphenyl)neopentanamidine 131678-85-8P,
4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)mor
pholine 131678-87-0P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-
imidazolidinylideneamino)phenyl]morpholine 131678-88-1P,
1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine fumarate
131678-89-2P, N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine
monofumarate 131678-90-5P, 1-Butyl-2-(2-morpholinophenyl)-3-
ethylguanidine monofumarate 131678-92-7P, 1-Butyl-2-(5-methyl-2-
morpholinophenyl)-3-methylguanidine monofumarate 131678-93-8P,
1-Butyl-2-(6-methyl-2-morpholinophenyl)-3-methylguanidine 131678-94-9P,
1-Butyl-2-(6-methyl-2-morpholinomethyl)-3-methylguanidine monofumarate
131678-95-0P, 1,1-Dimethyl-2-(2-morpholino-5-trifluoromethylphenyl)guanidi
ne fumarate 131678-96-1P, 1,1-Dimethyl-2-(5-cyano-2-
morpholinophenyl)guanidine monofumarate 131678-98-3P,
1,1-Dimethyl-2-(5-chloro-2-morholinophenyl)guanidine monofumarate
131678-99-4P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine
fumarate 131679-00-0P, 1,1-Dimethyl-2-(3-methyl-2-
morpholinophenyl)guanidine fumarate 131679-01-1P, N,N-Dimethyl-N'-(2-
morpholinomethylphenyl)guanidine 131679-03-3P, 4-[2-(1-Benzyl-3-methyl-2-
pyrrolidinylideneamino)phenyl]morpholine 131679-07-7P,
4-(2-[1-Methyl-3-(2-acetoxyethyl)-2-imidazolidenylideneamino]phenyl)morpho
line 131679-37-3P, 1-Butyl-3-(5-chloro-2-morpholinophenyl)thiourea
131679-38-4P 131679-40-8P 131679-42-0P 131679-45-3P,
1,1-Dimethyl-2-(2-morpholinophenyl)thiourea 131679-46-4P,
2-Methyl-1-(2-morpholinophenyl)-3,3-dimethyl-2-thiopseudourea
131697-93-3P 131697-94-4P 131697-95-5P 131697-96-6P 131697-97-7P
131697-98-8P 131697-99-9P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-
imidazolidenylideneamino)phenyl]morpholine monofumarate 131698-00-5P

131698-01-6P 131698-02-7P, 1,1-Dimethyl-2-(4-methoxy-2-morpholinophenyl)guanidine 143803-94-5P 143803-95-6P 143803-96-7P 143803-99-0P 143804-00-6P 143804-01-7P 143804-02-8P 143804-03-9P, N-(2-Morpholinomethyl)butyramidine 143804-04-0P, N-(5-Methylthio-2-morpholinophenyl)isobutyramidine 143804-05-1P, 4-[2-(3-Morpholinylideneamino)phenyl]morpholine 143804-06-2P 143804-07-3P 143804-08-4P, 2-(2-Morpholinomethyl)-1,1,3,3-tetramethylguanidine 143804-09-5P, 4-(2-[1-(2-Formyloxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine 143804-10-8P, 1-(2-Methoxyethyl)-2-(2-piperidinylphenyl)guanidine 143804-11-9P, 1-Methyl-3-[2-(1-pyrrolidinyl)phenyl]urea 143804-12-0P, 1-Methyl-3-(5-methyl-2-morpholinophenyl)urea 143804-13-1P, 1-Methyl-2-(2-morpholinophenyl)-3-pentylguanidine 143804-14-2P 143804-15-3P 143804-16-4P, 4-[2-(1,3-Dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 144187-06-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine maleate 144187-07-5P 144187-08-6P 144187-09-7P 144187-11-1P 144187-12-2P 144187-13-3P 144187-14-4P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monotartrate 144187-15-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemisulfate 144187-16-6P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemipamoate 144187-17-7P, N-(2-Morpholinomethyl)butyramidine fumarate 144187-19-9P, N-Methyl-N'-(2-morpholinomethylbenzyl)neopentanamidine monofumarate 144187-20-2P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine monofumarate 144187-21-3P 144187-22-4P, 1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine monofumarate 144187-23-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine monofumarate 144187-24-6P, 1-(2-Methoxyethyl)-2-(2-piperidinophenyl)guanidine hemifumarate 144187-25-7P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-methoxyethyl)guanidine hemifumarate 144187-26-8P, 1-Allyl-2-[2-(1-pyrrolidinyl)phenyl]-3-methylguanidine monofumarate 144187-27-9P, 4-(2[-1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl)morpholine.2/3 fumarate 144187-28-0P, 1-Methyl-2-(2-morpholinophenyl)-3-valeramidine monofumarate 144187-29-1P, 2-Methyl-1-(6-methyl-2-morpholinophenyl)-3-methyl-2-thiopseudourea hydriodide 144187-32-6P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine monofumarate
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypoglycemic)

IT 80-73-9P, 1,3-Dimethyl-2-imidazolidinone 1530-89-8P, 4-Cyanomorpholine 3699-54-5P, 1-(2-Hydroxyethyl)-2-imidazolinone 51317-68-1P, 2-Piperidinophenyl isothiocyanate 67829-55-4P, 1-[2-(1-Pyrrolidinyl)phenyl]urea 95539-61-0P, 4-(2-Aminobenzyl)morpholine 131679-04-4P 131679-05-5P 131679-06-6P 131679-08-8P, 1-[2-(4-Morpholino)phenyl]thiourea 131679-09-9P 131679-12-4P 131679-13-5P, 2-[Bis(2-methoxyethyl)amino]phenyl isothiocyanate 131679-14-6P 131679-15-7P 131679-16-8P, 2-Thiamorpholinophenyl isothiocyanate 131679-18-0P 131679-21-5P 131679-22-6P, 5-Methyl-2-morpholinophenyl isothiocyanate 131679-23-7P, 1-(5-Methyl-2-morpholinophenyl)thiourea 131679-24-8P, 1-[2-(2-Methyl-1-pyrrolidinyl)phenyl]thiourea 131679-25-9P 131679-26-0P, 1-(2-Piperidinophenyl)thiourea 131679-27-1P 131679-28-2P, 6-Methyl-2-piperidinophenyl isocyanate 131679-29-3P 131679-30-6P, N-(2-Hydroxyethyl)-1,2-dimethyl-1,2-ethylenediamine 131679-31-7P, 1-(2-Morpholinophenyl)-3-methylthiourea 131679-32-8P, 2-Methyl-1-(2-morpholinophenyl)guanidine 131679-36-2P 131679-44-2P 131679-50-0P 131679-52-2P 131679-53-3P 131679-54-4P 131679-55-5P 131679-56-6P 131679-57-7P 131679-58-8P 131679-59-9P 131679-60-2P 131679-61-3P 131679-62-4P 131679-63-5P 131679-64-6P, N-(2-Morpholinophenyl)-N-cyanoamine 131679-65-7P, N-Methyl-N'-(2-morpholinophenyl)carbodiimide 131679-66-8P 131679-67-9P 131698-05-0P, 1-(6-Methyl-2-piperidinophenyl)thiourea 131698-06-1P 144187-33-7P, 6-Methyl-2-morpholinophenyl isothiocyanate 144187-34-8P, 1-(6-Methyl-2-morpholinophenyl)urea 144187-36-0P, 1-(2-

Thiamorpholinophenyl)urea 144187-37-1P, 3-Benzoyl-1-[2-(1-pyrrolidinyl)phenyl]urea 144187-38-2P 144187-39-3P, 1-Ethyl-3-(2-morpholinophenyl)urea 144187-40-6P 144187-41-7P, 1-Butyl-3-(2-morpholinophenyl)pseudourea 144187-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for hypoglycemics)

IT 57-13-6, Urea, reactions 74-88-4, Methyl iodide, reactions 75-21-8, Oxirane, reactions 78-82-0, Isobutyronitrile 80-48-8, Methyl p-toluenesulfonate 93-97-0, Benzoyl anhydride 107-15-3, 1,2-Ethanediamine, reactions 109-11-5, 3-Morpholinone 109-73-9, Butylamine, reactions 109-74-0, Butyronitrile 109-81-9 110-59-8, Valeronitrile 110-60-1, 1,4-Butanediamine 111-41-1, N-(2-Hydroxyethyl)-1,2-ethylenediamine 124-40-3, Dimethylamine, reactions **130-85-8**, Pamoic acid 463-71-8, Thiophosgene 532-55-8, Benzoyl isothiocyanate 556-61-6, Methyl isothiocyanate 563-86-0, 1,2-Dimethylethylenediamine 592-82-5, Butyl isothiocyanate 630-18-2 632-22-4, Tetramethylurea 675-20-7, 2-Piperidinone 784-57-6, 2-Morpholino-5-(trifluoromethyl)aniline 872-50-4, 1-Methyl-2-pyrrolidinone, reactions 1003-03-8, Cyclopentylamine 1467-79-4, N,N-Dimethylcyanamide 5370-33-2, 1,3,3-Trimethyl-2-pyrrolidinone 5448-29-3, N'-Isopropyl-2-methyl-1,2-propanediamine 5585-33-1 6291-84-5, 3-(Methylamino)propylamine 6830-83-7 21627-58-7, 1-(2-Aminophenyl)pyrrolidine 22455-69-2 26586-18-5, 4-(2-Amino-4-methoxycarbonylphenyl)morpholine 39643-31-7, 2-Piperidinoaniline 39799-78-5, 1,3-Dimethyl-2-imidazolinone 50533-97-6, 4-(Dimethylamino)piperidine 51317-67-0 59504-49-3 84186-31-2, 6-Methyl-2-piperidinoaniline 90875-44-8, 4-(2-Amino-4-chlorophenyl)morpholine 91429-92-4, 4-(2-Amino-4-methylphenyl)morpholine 108303-99-7, 1-Benzyl-3-methyl-2-pyrrolidinone 113502-25-3, 3-Ethyl-1,1,3-trimethylurea 131679-48-6, 2-Morpholino-5-(trimethylmethyl)phenyl isothiocyanate 131679-49-7 144187-42-8, 1-Methyl-3-(2-methoxyethyl)-2-piperidinone 144187-43-9, 5-(Methylthio)-2-morpholinoaniline 144187-44-0, 5-Fluoro-2-morpholinoaniline 144187-45-1, 4-(2-Amino-4-chlorobenzyl)morpholine 144187-46-2, 3-Allyl-2-(2-morpholinophenyl)-1,3,3-trimethylurea 144187-47-3, 3-Butyl-1,1,3-trimethylurea 144187-48-4 144187-50-8, 6-Methyl-2-morpholinoaniline 144187-51-9, N,N-Bis(2-methoxyethyl)benzene-1,2-diamine 144187-52-0, 2-Thiomorpholinoaniline 144187-53-1, 2-Methyl-1-(2-aminophenyl)pyrrolidine 144187-54-2 144187-55-3, 4-(2-Aminophenyl)morpholine hydrochloride 144187-56-4, 4-Methoxy-2-morpholinoaniline 144187-57-5, 5-Isobutyl-2-morpholinoaniline hydrochloride
RL: RCT (Reactant)
(reaction of, in prepn. of hypoglycemics)

IT **130-85-8**, Pamoic acid
RL: RCT (Reactant)
(reaction of, in prepn. of hypoglycemics)

RN 130-85-8 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)



L76 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:598202 HCAPLUS
DN 115:198202
TI Effect of the lysosomotropic drug suramin on islet lysosomal enzyme activities and the insulin-secretory response induced by various secretagogues
AU Panagiotidis, Georgios; Salehi, Albert A.; Lundquist, Ingmar
CS Fac. Health Sci., Univ. Linkoeping, Linkoeping, S-581 85, Swed.
SO Pharmacology (1991), 43(3), 163-8
CODEN: PHMGBN; ISSN: 0031-7012
DT Journal
LA English
CC 1-10 (Pharmacology)
AB The trypanocidal drug suramin is known to conc. in lysosomes and to depress the activity of different lysosomal enzymes. The authors have shown previously that suramin can inhibit the activity of the islet lysosomal enzyme acid amyloglucosidase, a glycogenolytic glucose-producing hydrolase, which seems to be involved in certain insulin-secretory processes. In the present investigation they studied the pH dependency and dose-response effects of suramin on islet lysosomal enzyme activities as well as the effect of suramin treatment on the insulin-secretory response to various secretagogues in mice. It was found that two injections of suramin (0.18 mmol/kg) to normal NMRI mice at -24 and -2 h induced a moderate depression of the activities of islet acid amyloglucosidase (-22%) and acid phosphatase (-13%), whereas no effect was recorded for the activities of acid .alpha.-glucosidase, N-acetyl-.beta.-D-glucosaminidase and the non-lysosomal enzyme neutral .alpha.-glucosidase. Direct addn. of different concns. of suramin to islet homogenates showed that the drug was a potent inhibitor of acid amyloglucosidase and acid .alpha.-glucosidase at pH 4.0. At pH 5.0, suramin induced a large increase in acid .alpha.-glucosidase activity, whereas acid amyloglucosidase and acid phosphatase were inhibited. Suramin-injected mice showed a reduced insulin-secretory response to the sulfonylurea drug glibenclamide (-45%), whereas the insulin response to the cholinergic agonist carbachol or the phosphodiesterase inhibitor IBMX (1-isobutyl-3-methylxanthine) was unaffected. Thus, suramin inhibits islet acid amyloglucosidase activity in vivo and in vitro, whereas its effect on acid .alpha.-glucosidase is complex and pH dependent. The inhibitory effect of suramin on the glibenclamide-stimulated insulin response lends further support to the hypothesis that islet amyloglucosidase is involved in sulfonylurea-induced insulin secretion.
ST suramin pancreatic islet enzyme insulin secretion
IT Pancreatic islet of Langerhans
(lysosomal enzymes of, suramin effect on, insulin secretion in relation to)
IT Lysosome
(of pancreatic islets of Langerhans, enzymes of, suramin effect on, insulin secretion in relation to)

IT Sulfonamides
RL: BIOL (Biological study)
(sulfonylureas, insulin secretion induced by, suramin effect on, lysosomal enzymes in relation to)

IT 51-83-2 1023-21-8 28822-58-4
RL: BIOL (Biological study)
(insulin secretion induced by, suramin effect on, lysosomal enzymes in relation to)

IT 9001-77-8, Acid phosphatase 9012-33-3 9032-08-0, Amyloglucosidase 9033-06-1, Glucosidase
RL: BIOL (Biological study)
(of lysosomes, of pancreatic islets of Langerhans, suramin effect on, insulin secretion in relation to)

IT **145-63-1**, Suramin
RL: BIOL (Biological study)
(pancreatic islet of Langerhans lysosomal enzyme activities response to, insulin-secretory response to secretagogues in relation to)

IT **9004-10-8**, Insulin, biological studies
RL: BIOL (Biological study)
(secretion of, secretagogue-induced, suramin effect on, lysosomal enzymes in relation to)

IT **145-63-1**, Suramin
RL: BIOL (Biological study)
(pancreatic islet of Langerhans lysosomal enzyme activities response to, insulin-secretory response to secretagogues in relation to)

RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **9004-10-8**, Insulin, biological studies
RL: BIOL (Biological study)
(secretion of, secretagogue-induced, suramin effect on, lysosomal enzymes in relation to)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:400778 HCAPLUS
DN 115:778
TI Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IN Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett J.; Fritzberg, Alan R.
PA NeoRx Corp., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K047-00
ICS A61K049-02; A61K043-00
CC 1-6 (Pharmacology)
Section cross-reference(s): 8, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 359347	A2	19900321	EP 1989-250014	19890814
	EP 359347	A3	19900418		
	EP 359347	B1	19921223		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5135736	A	19920804	US 1988-232337	19880815
	US 5169933	A	19921208	US 1989-390241	19890807
	CA 1334513	A1	19950221	CA 1989-608198	19890811
	JP 02124833	A2	19900514	JP 1989-209992	19890814
	AT 83669	E	19930115	AT 1989-250014	19890814
PRAI	US 1988-232337		19880815		
	EP 1989-250014		19890814		

AB Covalently-linked complexes (CLCs) for targeting a defined population of cells comprise a targeting protein (e.g. antibody, hormone, enzyme, etc.), a cytotoxic agent (e.g. radionuclide, toxin, drug, etc.) an enhancing moiety capable of enhancing CLC-target cell interaction (e.g. a translocating/internalizing moiety, an anchoring peptide, membrane-sol. hydrophobic mol., etc.). The CLCs are used to enhance in vivo cytotoxicity and imaging (no data). Translocating peptide, Cys-Gly-Glu-Ala-Ala-Leu-Ala(Glu-Ala-Leu-Ala)4-Glu-Ala-Leu-Glu-Ala-Leu-Ala-Ala-NH2, is conjugated via succinimidyl 4(N-maleimidemethyl)cyclohexane-1-

carboxylate (SMCC) to reduced toxin A chain. The conjugate is reacted with iminothiolane to generate further thiol groups which are then bonded to reduced antibody to prep. translocating peptide-ricin A chain-antibody CLC.

ST targeting protein cytotoxin enhancer conjugate; translocating peptide ricin antibody conjugate; imaging radionuclide targeting protein enhancer conjugate

IT Animal cell
(agents enhancing covalently-linked complex interaction with, conjugates with cytotoxic agent and targeting protein)

IT Clathrins
RL: BIOL (Biological study)
(antibodies to, conjugates with cytotoxic agent and targeting protein)

IT Antigens
RL: BIOL (Biological study)
(antibody to binding region of, conjugates with cytotoxic agent and target cell interaction enhancers)

IT Pokeweed
(antiviral proteins of, conjugates with targeting protein and target cell interaction enhancer)

IT Antibodies
RL: BIOL (Biological study)
(as targeting protein in conjugates with cytotoxic agent and target cell interaction enhancers)

IT Anesthetics
Animal growth regulators
RL: BIOL (Biological study)
(conjugates with cytotoxic agent and targeting protein)

IT Cytotoxic agents
Fluorescent substances
Pharmaceuticals
Toxins
RL: BIOL (Biological study)
(conjugates with targeting protein and target cell interaction enhancer)

IT Pseudomonas
(exotoxin A of, conjugates with targeting protein and target cell interaction enhancer)

IT Virus
(fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)

IT Membrane, biological
(mol. sol. in, conjugates with cytotoxic agent and targeting protein)

IT Venoms
(peptides of, of snake, conjugates with targeting protein and target cell interaction enhancer)

IT Barley
(toxins of, conjugates with targeting protein and target cell interaction enhancer)

IT Snake
(venom peptides of, conjugates with targeting protein and target cell interaction enhancer)

IT Radioelements, compounds
RL: BIOL (Biological study)
(Auger electron-emitting, conjugates, with targeting protein and target cell interaction enhancer)

IT Virus, animal
(Sendai, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)

IT Toxins
RL: BIOL (Biological study)
(Shiga, conjugates with targeting protein and target cell interaction enhancer)

IT Radioelements, compounds
RL: BIOL (Biological study)
(X-ray-emitting, conjugates, with targeting protein and target cell interaction enhancer)

IT Radioelements, compounds
RL: BIOL (Biological study)
(alpha-particle-emitting, conjugates, with targeting protein and target cell interaction enhancer)

IT Fatty acids, compounds
RL: BIOL (Biological study)
(analogs, conjugates, with cytotoxic agent and targeting protein)

IT Proteins, specific or class
RL: BIOL (Biological study)
(antiviral, of pokeweed, conjugates with targeting protein and target cell interaction enhancer)

IT Lipoproteins
RL: BIOL (Biological study)
(apo-, A-I, conjugates, with cytotoxic agent and targeting protein)

IT Lipoproteins
RL: BIOL (Biological study)
(apo-, B, conjugates, with cytotoxic agent and targeting protein)

IT Radioelements, compounds
RL: BIOL (Biological study)
(beta-particle-emitting, conjugates, with targeting protein and target cell interaction enhancer)

IT Avidins
Enzymes
Peptides, compounds
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and target cell interaction enhancers, for cell targeting for enhanced cytotoxicity)

IT Bile acids
Estrogens
Fatty acids, compounds
Phospholipids, compounds
Transferrins
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and targeting protein)

IT Leupeptins
Phosphatidylinositols
RL: BIOL (Biological study)
(conjugates, with cytotoxic agent and targeting protein, cell targeting with, for enhanced cytotoxicity and imaging)

IT Abrins
Radioelements, compounds
Ricins
RL: BIOL (Biological study)
(conjugates, with targeting protein and target cell interaction enhancer)

IT Radiography
Scintigraphy
Tomography
(contrast agents, covalently linked complexes contg. cytotoxic agent and targeting protein and enhancing moiety as)

IT Toxins
RL: BIOL (Biological study)
(cyto-, conjugates with targeting protein and target cell interaction enhancer)

IT Toxins
RL: BIOL (Biological study)
(diphtheria, conjugates with targeting protein and target cell interaction enhancer)

IT Toxins

RL: BIOL (Biological study)
(exo-, A, of Pseudomonas, conjugates with targeting protein and target cell interaction enhancer)
IT Proteins, specific or class
RL: BIOL (Biological study)
(fusion products, conjugates, with cytotoxic agent and targeting protein)
IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(galactose-contg., conjugates, with cytotoxic agent and targeting protein)
IT Radioelements, compounds
RL: BIOL (Biological study)
(gamma-ray-emitting, conjugates, with targeting protein and target cell interaction enhancer)
IT Ribonucleic acid formation factors
RL: BIOL (Biological study)
(gene tat, conjugates with cytotoxic agent and targeting protein)
IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(glucose-contg., conjugates, with cytotoxic agent and targeting protein)
IT Virus, animal
(human immunodeficiency, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
IT Virus, animal
(measles, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
IT Glycerides, compounds
RL: BIOL (Biological study)
(medium-chain, conjugates, with cytotoxic agent and targeting protein)
IT Antibodies
RL: SPN (Synthetic preparation); PREP (Preparation)
(monoclonal, conjugates with chelated radiolabel and anchoring peptide, prepn. of, for cell targeting)
IT Virus, animal
(murine mammary tumor, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
IT Toxins
RL: BIOL (Biological study)
(pertussis, conjugates with targeting protein and target cell interaction enhancer)
IT Proteins, specific or class
RL: BIOL (Biological study)
(pore-forming, conjugates, with cytotoxic agent and targeting protein)
IT Radioelements, compounds
RL: BIOL (Biological study)
(positron-emitting, conjugates, with targeting protein and target cell interaction enhancer)
IT Virus, animal
(respiratory syncytial, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
IT Proteins, specific or class
RL: BIOL (Biological study)
(saporins, conjugates, with targeting protein and target cell interaction enhancer)
IT Peptides, compounds
RL: BIOL (Biological study)
(signal, conjugates, with cytotoxic agent and targeting protein)
IT Virus, animal
(simian immunodeficiency, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)
IT Virus, animal

(simian retro-, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)

IT Biological transport
(translocation, agents for, conjugates with cytotoxic agent and targeting protein)

IT Proteins, specific or class
RL: BIOL (Biological study)
(tritins, conjugates, with targeting protein and target cell interaction enhancer)

IT Virus, animal
(visna, fusion peptide anchoring sequences of, conjugates with cytotoxic agent and targeting protein)

IT Hemolysins
RL: BIOL (Biological study)
(.delta.-, conjugates, with cytotoxic agent and targeting protein)

IT Carbohydrates and Sugars, compounds
RL: BIOL (Biological study)
(N-acetylglucosamine-contg., conjugates, with cytotoxic agent and targeting protein)

IT 50-18-0D, Cyclophosphamide, conjugates with targeting protein and target cell interaction enhancer 51-21-8D, 5-Fluorouracil, conjugates with targeting protein and target cell interaction enhancer 54-42-2D, Iododeoxyuridine, conjugates with targeting protein and target cell interaction enhancer 56-81-5D, 1,2,3-Propanetriol, conjugates with cytotoxic agent and targeting protein 59-05-2D, Methotrexate, conjugates with targeting protein and target cell interaction enhancer 59-43-8D, Thiamine, conjugates with cytotoxic agent and targeting protein 66-72-8D, Pyridoxal, conjugates with cytotoxic agent and targeting protein 79-83-4D, Pantothenic acid, conjugates with cytotoxic agent and targeting protein 112-79-8D, Elaidic acid, conjugates with cytotoxic agent and targeting protein 123-39-7D, N-Methylformamide, conjugates with targeting protein and target cell interaction enhancer 128-13-2D, Ursodeoxycholic acid, conjugates with cytotoxic agent and targeting protein 133-89-1D, UDP-glucose, conjugates with cytotoxic agent and targeting protein 135-16-0D, conjugates with cytotoxic agent and targeting protein 137-58-6D, Lidocaine, conjugates with cytotoxic agent and targeting protein **145-63-1D**, Suramin, conjugates with targeting protein and target cell interaction enhancer 147-94-4D, Cytarabine, conjugates with targeting protein and target cell interaction enhancer 148-82-3D, Melphalan, conjugates with targeting protein and target cell interaction enhancer 154-42-7D, 6-Thioguanine, conjugates with targeting protein and target cell interaction enhancer 320-67-2D, Azacitidine, conjugates with targeting protein and target cell interaction enhancer 459-86-9D, Mitoguazone, conjugates with targeting protein and target cell interaction enhancer 474-25-9D, Chenodeoxycholic acid, conjugates with cytotoxic agent and targeting protein 512-64-1D, Echinomycin, conjugates with targeting protein and target cell interaction enhancer 528-04-1D, conjugates with cytotoxic agent and targeting protein 528-74-5D, Dichloromethotrexate, conjugates with targeting protein and target cell interaction enhancer 544-63-8D, Tetradecanoic acid, conjugates with cytotoxic agent and targeting protein 645-05-6D, Hexamethylmelamine, conjugates with targeting protein and target cell interaction enhancer 693-72-1D, trans-Vaccenic acid, conjugates with cytotoxic agent and targeting protein 865-21-4D, Vinblastine, conjugates with targeting protein and target cell interaction enhancer 2956-16-3D, UDP-galactose, conjugates with cytotoxic agent and targeting protein 3063-71-6D, conjugates with cytotoxic agent and targeting protein 3375-50-6D, conjugates with targeting protein and target cell interaction enhancer 3616-06-6D, UDP-xylose, conjugates with cytotoxic agent and targeting protein 3672-15-9D, Mannose-6-phosphate, conjugates with cytotoxic agent and targeting protein 3778-73-2D, Ifosfamide, conjugates with targeting protein and target cell interaction enhancer 4005-51-0D, 2-Amino-1,3,4-thiadiazole, conjugates with targeting protein and target

cell interaction enhancer 6082-29-7D, conjugates with cytotoxic agent and targeting protein 6990-06-3D, Fusidic acid, conjugates with cytotoxic agent and targeting protein 7440-16-6D, Rhodium, conjugates with targeting protein and target cell interaction enhancer 7481-89-2D, Dideoxycytidine, conjugates with targeting protein and target cell interaction enhancer 9002-64-6D, Parathyroid hormone, conjugates with cytotoxic agent and targeting protein **9004-10-8D**, Insulin, conjugates with cytotoxic agent and targeting protein 9007-12-9D, Calcitonin, conjugates with cytotoxic agent and targeting protein 9007-92-5D, Glucagon, conjugates with cytotoxic agent and targeting protein 9015-68-3D, Asparaginase, conjugates with targeting protein and target cell interaction enhancer 10043-49-9D, Gold-198, conjugates with targeting protein and target cell interaction enhancer 10043-66-0D, Iodine-131, conjugates with targeting protein and target cell interaction enhancer 10098-91-6D, Yttrium-90, conjugates with targeting protein and target cell interaction enhancer 10318-26-0D, Dibromodulcitol, conjugates with targeting protein and target cell interaction enhancer 11056-06-7D, Bleomycin, conjugates with targeting protein and target cell interaction enhancer 13494-90-1D, Gallium nitrate, conjugates with targeting protein and target cell interaction enhancer 13551-87-6D, Misonidazole, conjugates with targeting protein and target cell interaction enhancer 13909-02-9D, 1-(2-Chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea, conjugates with targeting protein and target cell interaction enhancer 13909-09-6D, Semustine, conjugates with targeting protein and target cell interaction enhancer 13981-22-1D, Nitrogen-13, conjugates with targeting protein and target cell interaction enhancer 13981-25-4D, Copper-64, conjugates with targeting protein and target cell interaction enhancer 13981-51-6D, Mercury-197, conjugates with targeting protein and target cell interaction enhancer 13981-56-1D, Fluorine-18, conjugates with targeting protein and target cell interaction enhancer 13982-43-9D, Oxygen-15, conjugates with targeting protein and target cell interaction enhancer 14119-09-6D, Gallium-67, conjugates with targeting protein and target cell interaction enhancer 14158-31-7D, Iodine-125, conjugates with targeting protein and target cell interaction enhancer 14333-33-6D, Carbon-11, conjugates with targeting protein and target cell interaction enhancer 14378-26-8D, Rhenium-188, conjugates with targeting protein and target cell interaction enhancer 14378-53-1D, Rhodium-101, conjugates with targeting protein and target cell interaction enhancer 14391-96-9D, Scandium-47, conjugates with targeting protein and target cell interaction enhancer 14687-25-3D, Lead-203, conjugates with targeting protein and target cell interaction enhancer 14769-73-4D, Levamisole, conjugates with targeting protein and target cell interaction enhancer 14809-46-2D, Selenium-72, conjugates with targeting protein and target cell interaction enhancer 14809-47-3D, Bromine-75, conjugates with targeting protein and target cell interaction enhancer 14834-67-4, Iodine-133, biological studies 14834-68-5D, Iodine-135, conjugates with targeting protein and target cell interaction enhancer 14913-49-6D, Bismuth-212, conjugates with targeting protein and target cell interaction enhancer 14914-02-4D, conjugates with targeting protein and target cell interaction enhancer 14914-68-2D, conjugates with targeting protein and target cell interaction enhancer 14981-64-7D, Palladium-109, conjugates with targeting protein and target cell interaction enhancer 14998-63-1D, Rhenium-186, conjugates with targeting protein and target cell interaction enhancer 15092-94-1D, Lead-212, conjugates with targeting protein and target cell interaction enhancer 15411-62-8D, Ruthenium-99, conjugates with targeting protein and target cell interaction enhancer 15663-27-1D, cis-Platinum, conjugates with targeting protein and target cell interaction enhancer 15690-69-4D, Palladium-100, conjugates with targeting protein and target cell interaction enhancer 15715-08-9D, conjugates with targeting protein and target cell interaction enhancer 15741-25-0D, Barium-128, conjugates with targeting protein and target cell interaction enhancer 15750-15-9D, Indium-111, conjugates with targeting protein and target cell interaction enhancer 15755-33-6D, Arsenic-72,

conjugates with targeting protein and target cell interaction enhancer 15755-39-2D, Astatine-211, conjugates with targeting protein and target cell interaction enhancer 15757-14-9D, Gallium-68, conjugates with targeting protein and target cell interaction enhancer 15757-86-5D, Copper-67, conjugates with targeting protein and target cell interaction enhancer 15765-38-5D, Bromine-76, conjugates with targeting protein and target cell interaction enhancer 15765-39-6D, Bromine-77, conjugates with targeting protein and target cell interaction enhancer 15839-70-0D, GDP-fucose, conjugates with cytotoxic agent and targeting protein 16468-59-0D, conjugates with targeting protein and target cell interaction enhancer 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 20449-79-0D, Melittin, conjugates with cytotoxic agent and targeting protein 20537-88-6D, Ethiofos, conjugates with targeting protein and target cell interaction enhancer 22668-01-5D, conjugates with targeting protein and target cell interaction enhancer 23205-42-7D, 3-Deazauridine, conjugates with targeting protein and target cell interaction enhancer 23214-92-8D, Doxorubicin, conjugates with targeting protein and target cell interaction enhancer 23491-44-3D, Pibenzimol, conjugates with targeting protein and target cell interaction enhancer 24584-09-6D, ICRF-187, conjugates with targeting protein and target cell interaction enhancer 26833-87-4D, Homoharringtonine, conjugates with targeting protein and target cell interaction enhancer 27061-78-5D, Alamethicin, conjugates with cytotoxic agent and targeting protein 29767-20-2D, Teniposide, conjugates with targeting protein and target cell interaction enhancer 31312-81-9D, Yttrium-80, conjugates with targeting protein and target cell interaction enhancer 31362-50-2D, Bombesin, conjugates with cytotoxic agent and targeting protein 31441-78-8D, Mercaptopurine, conjugates with targeting protein and target cell interaction enhancer 32954-58-8D, Ipomeanol, conjugates with targeting protein and target cell interaction enhancer 33069-62-4D, Taxol, conjugates with targeting protein and target cell interaction enhancer 41575-94-4D, Carboplatin, conjugates with targeting protein and target cell interaction enhancer 41992-23-8D, Spirogermanium, conjugates with targeting protein and target cell interaction enhancer 42228-92-2D, conjugates with targeting protein and target cell interaction enhancer 51264-14-3D, Amsacrine, conjugates with targeting protein and target cell interaction enhancer 51321-79-0D, PALA, conjugates with targeting protein and target cell interaction enhancer 51348-50-6D, .alpha.-L-Fucose, conjugates with cytotoxic agent and targeting protein 51724-48-2D, Trichothec-9-ene, conjugates with targeting protein and target cell interaction enhancer 52128-35-5D, Trimetrexate, conjugates with targeting protein and target cell interaction enhancer 53910-25-1D, Pentostatin, conjugates with targeting protein and target cell interaction enhancer 54749-90-5D, Chlorozotocin, conjugates with targeting protein and target cell interaction enhancer 56605-16-4D, conjugates with targeting protein and target cell interaction enhancer 57576-44-0D, Aclarubicin, conjugates with targeting protein and target cell interaction enhancer 57998-68-2D, Aziridinyl benzoquinone, conjugates with targeting protein and target cell interaction enhancer 59587-18-7D, conjugates with cytotoxic agent and targeting protein 59587-24-5D, conjugates with cytotoxic agent and targeting protein 59653-73-5D, Teroxirone, conjugates with targeting protein and target cell interaction enhancer 59763-91-6D, Pancreatic polypeptide, conjugates with cytotoxic agent and targeting protein 60084-10-8D, Tiazofurin, conjugates with targeting protein and target cell interaction enhancer 60617-12-1D, .beta.-Endorphin, conjugates with cytotoxic agent and targeting protein 61966-08-3D, Triciribine phosphate, conjugates with targeting protein and target cell interaction enhancer 62488-57-7D, conjugates with targeting protein and target cell interaction enhancer 62928-11-4D, Iproplatin, conjugates with targeting protein and target cell interaction enhancer 63521-85-7D, 4'-Deoxydoxorubicin, conjugates with targeting protein and target cell interaction enhancer 65271-80-9D, Mitoxantrone, conjugates with targeting protein and target cell interaction enhancer 65886-71-7D,

Fazarabine, conjugates with targeting protein and target cell interaction enhancer 69111-41-7D, conjugates with cytotoxic agent and targeting protein 69408-81-7D, conjugates with targeting protein and target cell interaction enhancer 70699-67-1D, Paradoxin, derivs., conjugates with cytotoxic agent and targeting protein 71628-96-1D, Menogaril, conjugates with targeting protein and target cell interaction enhancer 73027-21-1D, derivs., conjugates with cytotoxic agent and targeting protein 75607-67-9D, Fludarabine phosphate, conjugates with targeting protein and target cell interaction enhancer 77327-05-0D, Didemnin B, conjugates with targeting protein and target cell interaction enhancer 79152-85-5D, conjugates with targeting protein and target cell interaction enhancer 81424-67-1D, Caracemide, conjugates with targeting protein and target cell interaction enhancer 87626-55-9D, Flavone-8-acetic acid, conjugates with targeting protein and target cell interaction enhancer 89149-10-0D, Deoxyspergualin, conjugates with targeting protein and target cell interaction enhancer 91441-23-5D, conjugates with targeting protein and target cell interaction enhancer 96249-43-3D, conjugates with cytotoxic agent and targeting protein 97534-21-9D, Merbarone, conjugates with targeting protein and target cell interaction enhancer 99278-10-1D, conjugates with cytotoxic agent and targeting protein 103233-04-1D, conjugates with cytotoxic agent and targeting protein 108026-95-5D, conjugates with cytotoxic agent and targeting protein 110064-88-5D, conjugates with cytotoxic agent and targeting protein 131256-61-6D, conjugates with cytotoxic agent and targeting protein 131256-82-1D, conjugates with cytotoxic agent and targeting protein 131256-85-4D, conjugates with cytotoxic agent and targeting protein 131257-09-5D, Bombolittin, conjugates with cytotoxic agent and targeting protein 131399-93-4D, derivs., conjugates with cytotoxic agent and targeting protein 131399-94-5D, conjugates with cytotoxic agent and targeting protein 131399-95-6D, conjugates with cytotoxic agent and targeting protein 131399-96-7D, conjugates with cytotoxic agent and targeting protein 131399-97-8D, conjugates with cytotoxic agent and targeting protein 131399-98-9D, conjugates with cytotoxic agent and targeting protein 131399-99-0D, conjugates with cytotoxic agent and targeting protein 131400-00-5D, conjugates with cytotoxic agent and targeting protein 131400-01-6D, conjugates with cytotoxic agent and targeting protein 131400-02-7D, conjugates with cytotoxic agent and targeting protein 131400-03-8D, conjugates with cytotoxic agent and targeting protein 131400-04-9D, conjugates with cytotoxic agent and targeting protein 131400-05-0D, conjugates with cytotoxic agent and targeting protein 131400-06-1D, conjugates with cytotoxic agent and targeting protein 131400-07-2D, conjugates with cytotoxic agent and targeting protein 131400-08-3D, conjugates with cytotoxic agent and targeting protein

RL: BIOL (Biological study)
(cell targeting with, for enhanced cytotoxicity and imaging)

IT 58-85-5D, Biotin, conjugates with cytotoxic agent and target cell interaction enhancers
RL: BIOL (Biological study)
(for cell targeting for enhanced cytotoxicity and imaging)

IT 14133-76-7D, Technetium-99, conjugates with targeting protein and target cell interaction enhancer
RL: BIOL (Biological study)
(metastable, cell targeting with, for enhanced cytotoxicity and imaging)

IT 96573-46-5 99616-33-8 99896-85-2 110590-64-2
RL: BIOL (Biological study)
(peptides contg., conjugates with cytotoxic agent and targeting protein)

IT 14378-26-8DP, complexes with GABA deriv., conjugates with monoclonal antibody and anchoring peptide 131418-21-8DP, rhenium-188 complexes, conjugates with monoclonal antibody and anchoring peptide
RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as radionuclide-targeting protein-anchoring peptide covalently-linked complex for cell targeting)

IT 131400-09-4DP, conjugates with ricin A chain and antibody
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as translocating peptide-targeting protein-cytotoxic agent covalently-linked complex for cell targeting)

IT 544-63-8DP, Tetradecanoic acid, esters
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for conjugation with antibody fragment and cytotoxic agent)

IT 41191-04-2
RL: BIOL (Biological study)
(sol., cell targeting with, for enhanced cytotoxicity and imaging)

IT 65988-88-7D, Modeccin, conjugates 75037-46-6D, Gelonin, conjugates
RL: BIOL (Biological study)
(with targeting protein and target cell interaction enhancer)

IT **145-63-1D**, Suramin, conjugates with targeting protein and target cell interaction enhancer **9004-10-8D**, Insulin, conjugates with cytotoxic agent and targeting protein
RL: BIOL (Biological study)
(cell targeting with, for enhanced cytotoxicity and imaging)

RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:115074 HCAPLUS
DN 114:115074
TI Insulin potentiation therapy (IPT) and pharmaceuticals for viral diseases such as cancers and AIDS
IN Garcia y Bellon, Donato P.; Garcia, Donato P., Jr.; Ayre, Steven G.
PA Mex.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K037-26
NCL 514003000
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4971951	A	19901120	US 1987-77833	19870727
	CA 1299102	A1	19920421	CA 1987-539603	19870615
	US 5155096	A	19921013	US 1990-615621	19901119
PRAI	CA 1987-539603		19870615		
	US 1987-77833		19870727		

AB Viral diseases, e.g. cancers and AIDS, are treated by i.v. injection of insulin to induce hypoglycemia and increase cell membrane permeability, followed by parenteral injection of glucose, mixed with or in conjunction with, prescribed antiviral/antineoplastic drugs. Pharmaceutical compns. are also discussed. A patient with AIDS and herpes zoster infection was treated with IPT twice a week in which 6 units insulin were given i.v. After 20 min, 30 mg ribavirin mixed with 50 mL of 50% hypertonic glucose was injected i.v. Antineoplastic drugs, cyclophosphamide 10 and methotrexate 0.5 mg, along with vitamin B complex were concurrently administered. On nontreatment days, the patient took 200 mg ribavirin orally daily, etc. At the end of the 3rd treatment, the herpes zoster had cleared and other symptoms improved. Treatment of various cancers is also described.
ST insulin potentiation therapy virus cancer; AIDS insulin potentiation therapy; herpes zoster insulin potentiation therapy
IT Pharmaceutical dosage forms
(for insulin potentiation therapy of viral infection and cancer)
IT Hypoglycemia
(induction of, with insulin in potentiation therapy of viral infection and cancer)

IT Virus, animal
(infection with, insulin potentiation therapy of)
IT Neoplasm inhibitors
Virucides and Virustats
(potentiation of, with insulin)
IT Sarcoma
(Ewing's, bone, treatment of, insulin potentiation therapy in)
IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, insulin potentiation therapy in)
IT Carcinoma
(adeno-, breast infiltrating, treatment of, insulin potentiation therapy in)
IT Lung, neoplasm
(adenocarcinoma, treatment of, insulin potentiation therapy in)
IT Uterus, neoplasm
(cervix, carcinoma, treatment of, insulin potentiation therapy in)
IT Virus, animal
(human immunodeficiency, infection with herpes zoster and, treatment of, insulin potentiation therapy in)
IT Virus, animal
(human immunodeficiency 1, infection with herpes zoster and, treatment of, insulin potentiation therapy in)
IT Pharmaceutical dosage forms
(injections, i.v., for insulin potentiation therapy of viral infection and cancer)
IT Virus, animal
(varicella-zoster, infection with AIDS virus and, treatment of, insulin potentiation therapy in)
IT 50-99-7, D-Glucose, biological studies
RL: BIOL (Biological study)
(in insulin potentiation therapy of viral infection and cancer)
IT 50-18-0 51-21-8, 5-Fluorouracil 59-05-2, Methotrexate **145-63-1**, Suramin 30516-87-1 36791-04-5, Ribavirin 89899-81-0, HPA-23
RL: PROC (Process)
(potentiation of, with insulin)
IT **9004-10-8**, Insulin, biological studies
RL: BIOL (Biological study)
(potentiation therapy of viral infection and cancer with)
IT **145-63-1**, Suramin
RL: PROC (Process)
(potentiation of, with insulin)
RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **9004-10-8**, Insulin, biological studies
RL: BIOL (Biological study)
(potentiation therapy of viral infection and cancer with)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L76 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS
AN 1986:1134 HCAPLUS
DN 104:1134
TI Islet lysosomal enzyme activities and plasma insulin levels in obese hyperglycemic mice following injection of the lysosomotropic drug suramin
AU Lundquist, Ingmar
CS Dep. Pharmacol., Univ. Lund, Lund, Swed.
SO Diabetes Res. (1985), 2(4), 207-11
CODEN: DIREEM
DT Journal
LA English
CC 2-6 (Mammalian Hormones)
Section cross-reference(s): 1, 14
AB The pattern of islet lysosomal enzyme activities and the plasma levels of insulin [**9004-10-8**] and glucose were studied in adult obese

hyperglycemic mice (aged 6-8 mo) after in vivo administration of the lysosomotropic drug suramin **[145-63-1]**. Suramin (5.2 .mu.mol/mouse) gradually decreased plasma insulin levels by .apprx.85% at 20 h postinjection. At the same time point the suramin-induced inhibition of insulin secretion was reflected by a notable (250%) increase in islet insulin content. A neg. correlation was obsd. between plasma insulin levels and islet insulin storage. Plasma glucose levels were not affected by the drug. The activity of acid amyloglucosidase [9032-08-0] in the islets, which is excessively high in the obese mouse, was reduced by .apprx.70% at 20 h after suramin. There was a good correlation between islet amyloglucosidase activity and the plasma insulin concn. in controls and suramin-treated mice. When glycogen was replaced by maltose or 4-methylumbelliferyl-.alpha.-D-glucoside as substrate for the acid .alpha.-1,4-glucoside splitting activity, the inhibitor effect of suramin was less pronounced (.apprx.50%). The ratio of glycogen-splitting to maltose-splitting activity in islet tissue was reduced by suramin from 1.25 (control) to 0.69. The neutral, nonlysosomal .alpha.-1,4-glucoside splitting activity was not affected by the drug. Apart from acid phosphatase activity, which was slightly inhibited, other islet lysosomal enzyme activities were not influenced by suramin administration. Apparently, islet lysosomal enzyme activities can be modulated independently by certain lysosomotropic drugs. Moreover, certain islet lysosomes and(or) lysosomal enzymes, notably acid amyloglucosidase, may be involved in certain insulin-releasing processes and hence may be implicated in the mechanisms of insulin hypersecretion in the obese ob/ob mouse.

ST pancreas islet lysosome insulin obesity; suramin lysosomal enzyme pancreas islet; obesity insulin lysosome pancreas islet

IT Lysosome
(enzymes of, of pancreas islet in obesity, insulin secretion in relation to)

IT Obesity
(insulin secretion in, lysosomal enzymes of pancreas islet in relation to)

IT Pancreatic islet of Langerhans
(lysosomal enzymes of, in hyperglycemia and obesity)

IT Enzymes
RL: BIOL (Biological study)
(of lysosomes, of pancreas islet in obesity, insulin secretion in relation to)

IT Blood sugar
(suramin effect on, in obesity, pancreas islet lysosomal enzymes in relation to)

IT **145-63-1**
RL: BIOL (Biological study)
(lysosomal enzymes of pancreas islet response to, insulin secretion in relation to)

IT 9032-08-0
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(of pancreas islet lysosome, suramin effect of, insulin secretion in relation to)

IT **9004-10-8**, biological studies
RL: BIOL (Biological study)
(secretion of, in hyperglycemia and obesity, lysosomal enzymes of pancreas islet in relation to)

IT **145-63-1**
RL: BIOL (Biological study)
(lysosomal enzymes of pancreas islet response to, insulin secretion in relation to)

RN 145-63-1 HCAPLUS

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **9004-10-8**, biological studies
RL: BIOL (Biological study)
(secretion of, in hyperglycemia and obesity, lysosomal enzymes of pancreas islet in relation to)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d his

(FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002
E HELMERHORST E/AU
L1 17 S E3,E4,E5
E PLEWRIGHT B/AU
L2 1 S E4
L3 17 S L1,L2

```
                E CURTIN/PA,CS
L4           3783 S E3-E49
L5              5 S L3 AND L4
L6             13 S L3 AND ?INSULIN?
L7              1 S L6 AND (NONPEPTID? OR NON PEPTID?)
L8              1 S L7 AND L5,L6
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002
L9             14 S E1-E14
L10            13 S L9 NOT INSULIN
L11             4 S L9 AND F/ELS
L12             1 S L11 AND 5/NR
L13            12 S L10 NOT L12
L14             8 S L13 AND OC5-C6/ES
L15             6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
L16             6 S L13 NOT L15
L17            12 S L10 NOT L12

     FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002
L18            16 S L3 NOT L8
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002
L19            13 S E15-E27
L20            12 S L19 NOT L9
L21         55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
L22           807 S L21 AND 26/C
L23           131 S L22 AND 5/O
L24            59 S L23 AND METHOXY
L25            46 S L24 NOT N/ELS
L26             4 S L22 AND C26H34O5
L27               STR
L28             0 S L27 CSS
L29             0 S L27 SAM
L30           437 S C26H34O5/MF
L31             6 S L30 AND 46.150.18/RID AND OC5-C6/ES
L32               STR L27
L33             1 S L32
L34            39 S L32 FUL
                SAV L34 HOPE400/A
L35            15 S L34 AND 3/NR
L36             8 S L35 NOT N/ELS
                SEL RN L20
                SEL RN L17
L37           763 S E40-E51/CRN
L38            63 S L37 NOT (COMPD OR MXS/CI)
L39            51 S L38 NOT WITH
L40            19 S L39 AND 4/NR
L41            18 S L40 NOT UNSPECIFIED
                SEL RN L12
L42             1 S E52/CRN
L43             2 S L12,L42
L44            30 S L17,L41

     FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

     FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002
L45             0 S L43

     FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002
L46            21 S L43
L47        140567 S INSULIN
```

```
L48       334734 S GLUCOSE
                 S INSULIN/CN OR GLUCOSE/CN

      FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002
L49            2 S GLUCOSE/CN

      FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002
L50       121055 S L49

      FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002
L51            1 S INSULIN/CN

      FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002
L52        71961 S L51
L53       172109 S L52 OR L50
L54           21 S L46 OR LY292728 OR LY()(292728 OR 292 728)
L55           16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)
L56            1 S L54 AND L3,L4
L57            1 S L54 AND L47,L48,L53
L58            1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L59            0 S L54 AND (?OBESIT? OR ?OBESE?)
L60            1 S L56-L58
                 E INSULIN/CT
                 E E24+ALL
L61         9442 S E11,E10
L62            1 S L54 AND L61
L63            1 S L60,L62
L64         1314 S L44
L65           61 S L64 AND L47,L48,L53,L61
L66         9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L67          458 S L61 AND (?OBESIT? OR ?OBESE?)
L68            8 S L65 AND L66,L67
L69         6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR
L70           34 S L69 AND L65
L71           33 S L70 NOT L68
L72            1 S L71 AND ?DIABET?
L73            2 S L63,L72
L74            9 S L51 AND L64
L75            8 S L74 NOT APOPTOSIS/TI
L76            9 S L73,L75
                 SEL HIT RN

      FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002
L77           14 S E1-E14
L78            1 S L77 NOT L43,L44

      FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002

      FILE 'BIOSIS' ENTERED AT 16:37:02 ON 23 MAY 2002
L79            1 S L54
L80         1962 S L44
L81           10 S L80 AND L51
L82            2 S L80 AND (?DIABET? OR ?HYPOGLYC? OR ?HYPO GLYC?)
L83           12 S L80 AND 17008/CC
L84           16 S L81-L83 AND PY<=1999
                 E HELMERHORST E/AU
L85           16 S E3,E4,E5
                 E PLEWRIGHT B/AU
L86            0 S L85 AND L79,L80
L87            9 S L84 NOT 240?/CC

      FILE 'EMBASE' ENTERED AT 16:41:17 ON 23 MAY 2002
                 E HELMERHORST E/AU
```

```
L88          22 S E3,E4
                E PLEWRIGHT B/AU
L89           3 S L54
L90        3270 S L44
L91           0 S L89,L90 AND L88
L92          20 S L89,L90 AND L51
L93           2 S L92 AND PY=1999

=> d his

     (FILE 'HOME' ENTERED AT 15:38:20 ON 23 MAY 2002)
                SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 15:38:31 ON 23 MAY 2002
                E HELMERHORST E/AU
L1           17 S E3,E4,E5
                E PLEWRIGHT B/AU
L2            1 S E4
L3           17 S L1,L2
                E CURTIN/PA,CS
L4         3783 S E3-E49
L5            5 S L3 AND L4
L6           13 S L3 AND ?INSULIN?
L7            1 S L6 AND (NONPEPTID? OR NON PEPTID?)
L8            1 S L7 AND L5,L6
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:41:55 ON 23 MAY 2002
L9           14 S E1-E14
L10          13 S L9 NOT INSULIN
L11           4 S L9 AND F/ELS
L12           1 S L11 AND 5/NR
L13          12 S L10 NOT L12
L14           8 S L13 AND OC5-C6/ES
L15           6 S L14 AND (C25H26O7 OR C28H36O7 OR C27H32N2O6 OR C26H34O7 OR C2
L16           6 S L13 NOT L15
L17          12 S L10 NOT L12

     FILE 'HCAPLUS' ENTERED AT 15:59:24 ON 23 MAY 2002
L18          16 S L3 NOT L8
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:59:39 ON 23 MAY 2002
L19          13 S E15-E27
L20          12 S L19 NOT L9
L21       55552 S 46.150.18/RID AND OC5-C6/ES AND 3/NR
L22         807 S L21 AND 26/C
L23         131 S L22 AND 5/O
L24          59 S L23 AND METHOXY
L25          46 S L24 NOT N/ELS
L26           4 S L22 AND C26H34O5
L27             STR
L28           0 S L27 CSS
L29           0 S L27 SAM
L30         437 S C26H34O5/MF
L31           6 S L30 AND 46.150.18/RID AND OC5-C6/ES
L32             STR L27
L33           1 S L32
L34          39 S L32 FUL
                SAV L34 HOPE400/A
L35          15 S L34 AND 3/NR
L36           8 S L35 NOT N/ELS
                SEL RN L20
```

```
                SEL RN L17
L37           763 S E40-E51/CRN
L38            63 S L37 NOT (COMPD OR MXS/CI)
L39            51 S L38 NOT WITH
L40            19 S L39 AND 4/NR
L41            18 S L40 NOT UNSPECIFIED
                SEL RN L12
L42             1 S E52/CRN
L43             2 S L12,L42
L44            30 S L17,L41

     FILE 'REGISTRY' ENTERED AT 16:19:44 ON 23 MAY 2002

     FILE 'HCAOLD' ENTERED AT 16:22:29 ON 23 MAY 2002
L45             0 S L43

     FILE 'HCAPLUS' ENTERED AT 16:22:38 ON 23 MAY 2002
L46            21 S L43
L47        140567 S INSULIN
L48        334734 S GLUCOSE
                S INSULIN/CN OR GLUCOSE/CN

     FILE 'REGISTRY' ENTERED AT 16:23:20 ON 23 MAY 2002
L49             2 S GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 16:23:20 ON 23 MAY 2002
L50        121055 S L49

     FILE 'REGISTRY' ENTERED AT 16:23:21 ON 23 MAY 2002
L51             1 S INSULIN/CN

     FILE 'HCAPLUS' ENTERED AT 16:23:21 ON 23 MAY 2002
L52         71961 S L51
L53        172109 S L52 OR L50
L54            21 S L46 OR LY292728 OR LY()(292728 OR 292 728)
L55            16 S L54 AND (PD<=19990922 OR PRD<=19990922 OR AD<=19990922)
L56             1 S L54 AND L3,L4
L57             1 S L54 AND L47,L48,L53
L58             1 S L54 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L59             0 S L54 AND (?OBESIT? OR ?OBESE?)
L60             1 S L56-L58
                E INSULIN/CT
                E E24+ALL
L61          9442 S E11,E10
L62             1 S L54 AND L61
L63             1 S L60,L62
L64          1314 S L44
L65            61 S L64 AND L47,L48,L53,L61
L66          9442 S L61 AND (?INSULIN? OR GLUCOSE OR BLOOD(L)SUGAR OR ?DIABET? OR
L67           458 S L61 AND (?OBESIT? OR ?OBESE?)
L68             8 S L65 AND L66,L67
L69          6995 S L65-L67 NOT INSULIN LIKE GROWTH FACTOR
L70            34 S L69 AND L65
L71            33 S L70 NOT L68
L72             1 S L71 AND ?DIABET?
L73             2 S L63,L72
L74             9 S L51 AND L64
L75             8 S L74 NOT APOPTOSIS/TI
L76             9 S L73,L75
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 16:35:44 ON 23 MAY 2002
L77            14 S E1-E14
```

```
L78           1 S L77 NOT L43,L44

     FILE 'HCAPLUS' ENTERED AT 16:36:35 ON 23 MAY 2002

     FILE 'BIOSIS' ENTERED AT 16:37:02 ON 23 MAY 2002
L79           1 S L54
L80        1962 S L44
L81          10 S L80 AND L51
L82           2 S L80 AND (?DIABET? OR ?HYPOGLYC? OR ?HYPO GLYC?)
L83          12 S L80 AND 17008/CC
L84          16 S L81-L83 AND PY<=1999
                E HELMERHORST E/AU
L85          16 S E3,E4,E5
                E PLEWRIGHT B/AU
L86           0 S L85 AND L79,L80
L87           9 S L84 NOT 240?/CC

     FILE 'EMBASE' ENTERED AT 16:41:17 ON 23 MAY 2002
                E HELMERHORST E/AU
L88          22 S E3,E4
                E PLEWRIGHT B/AU
L89           3 S L54
L90        3270 S L44
L91           0 S L89,L90 AND L88
L92          20 S L89,L90 AND L51
L93           2 S L92 AND PY=1999
                SET COST ON
```